+Follow
Sherry0000
No personal profile
112
Follow
8
Followers
0
Topic
0
Badge
Posts
Hot
Sherry0000
2022-07-18
👍🏻
Sorry, the original content has been removed
Sherry0000
2022-03-31
$KEPPEL INFRA TRUST WEF 2015(A7RU.SI)$
Good
Sherry0000
2022-07-20
Ok
Palantir: Possibly The Buy Of The Decade Now
Sherry0000
2022-04-12
$SINGAPORE AIRLINES LTD(C6L.SI)$
:)
Sherry0000
2021-12-28
Buy
Is Merck Stock A Buy Or Sell After FDA Authorizes Its Covid Pill?
Sherry0000
2022-06-05
👍🏻
Microsoft’s Dollar Alarm Raises New Worry for Software Stocks
Sherry0000
2022-03-29
$SINGAPORE AIRLINES LTD(C6L.SI)$
gogo
Sherry0000
01-24
$Vanguard S&P 500 ETF(VOO)$
oh yey
Sherry0000
2025-11-03
$Mapletree Log Tr(M44U.SI)$
Sherry0000
2022-09-29
👍🏻
US STOCKS-Wall Street Ends Sharply Higher as Treasury Yields Dip
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4094293265127660","uuid":"4094293265127660","gmtCreate":1631190560211,"gmtModify":1704447509378,"name":"Sherry0000","pinyin":"sherry0000","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":112,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.29","exceedPercentage":"60.87%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":"93.68%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":"93.25%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":4,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":525220862689528,"gmtCreate":1769253667813,"gmtModify":1769253670900,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&P 500 ETF(VOO)$ </a> oh yey ","listText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&P 500 ETF(VOO)$ </a> oh yey ","text":"$Vanguard S&P 500 ETF(VOO)$ oh yey","images":[{"img":"https://community-static.tradeup.com/news/c28aa3ccc44c53bd36c01c5ff7f7d5b8","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/525220862689528","isVote":1,"tweetType":1,"viewCount":78,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":525220194181832,"gmtCreate":1769253600759,"gmtModify":1769253604067,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&P 500 ETF(VOO)$ </a> ","listText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&P 500 ETF(VOO)$ </a> ","text":"$Vanguard S&P 500 ETF(VOO)$","images":[{"img":"https://community-static.tradeup.com/news/a09c6b4c7913918cac00f4938cb33e23","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/525220194181832","isVote":1,"tweetType":1,"viewCount":182,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":520758373863624,"gmtCreate":1768173531393,"gmtModify":1768173534575,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/M44U.SI\">$Mapletree Log Tr(M44U.SI)$ </a> ","listText":"<a href=\"https://ttm.financial/S/M44U.SI\">$Mapletree Log Tr(M44U.SI)$ </a> ","text":"$Mapletree Log Tr(M44U.SI)$","images":[{"img":"https://community-static.tradeup.com/news/881bd9d2e9c7d9a16f03a9b69eb9f569","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/520758373863624","isVote":1,"tweetType":1,"viewCount":265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":520095737356640,"gmtCreate":1768011656275,"gmtModify":1768011659123,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/A7RU.SI\">$Kep Infra Tr(A7RU.SI)$ </a> ","listText":"<a href=\"https://ttm.financial/S/A7RU.SI\">$Kep Infra Tr(A7RU.SI)$ </a> ","text":"$Kep Infra Tr(A7RU.SI)$","images":[{"img":"https://community-static.tradeup.com/news/1615eb5fa4ecfc0a78b8ac82d3a7ef33","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/520095737356640","isVote":1,"tweetType":1,"viewCount":357,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":496282594333192,"gmtCreate":1762185165675,"gmtModify":1762185168985,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/M44U.SI\">$Mapletree Log Tr(M44U.SI)$ </a> ","listText":"<a href=\"https://ttm.financial/S/M44U.SI\">$Mapletree Log Tr(M44U.SI)$ </a> ","text":"$Mapletree Log Tr(M44U.SI)$","images":[{"img":"https://community-static.tradeup.com/news/7414e839f24d8ffbecf94de3421f1873","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/496282594333192","isVote":1,"tweetType":1,"viewCount":925,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":492730718769704,"gmtCreate":1761318250620,"gmtModify":1761318254734,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"Woohoo","listText":"Woohoo","text":"Woohoo","images":[{"img":"https://community-static.tradeup.com/news/a1f036bdf659be2c3a14dda1ad06dfb3","width":"1125","height":"1476"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/492730718769704","isVote":1,"tweetType":1,"viewCount":905,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":303107606659184,"gmtCreate":1715036489324,"gmtModify":1715036493670,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$ </a> ","listText":"<a href=\"https://ttm.financial/S/META\">$Meta Platforms, Inc.(META)$ </a> ","text":"$Meta Platforms, Inc.(META)$","images":[{"img":"https://community-static.tradeup.com/news/318e5719309c97f718b054f0c09d7390","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/303107606659184","isVote":1,"tweetType":1,"viewCount":2532,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":200394607079424,"gmtCreate":1689955034716,"gmtModify":1689955040050,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/200394607079424","repostId":"200312277713072","repostType":1,"repost":{"id":200312277713072,"gmtCreate":1689926829486,"gmtModify":1689926956977,"author":{"id":"3527667647532483","authorId":"3527667647532483","name":"Option_Movers","avatar":"https://community-static.tradeup.com/news/165a4ccff157a147c5c40d359f9dc408","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667647532483","authorIdStr":"3527667647532483"},"themes":[],"title":"Option Movers|Tesla's Trading Volume Surged 103%; Netflix's $450 Call Worth Attention","htmlText":"The S&P 500 and Nasdaq fell on Thursday(July 20), weighed down by drops in Tesla and Netflix following their quarterly results.Regarding the options market, a total volume of 44,774,900 contracts was traded, up 4% from the previous trading day.Top 10 Option VolumesTop 10: <a href=\"https://ttm.financial/S/SPY\">$SPY(SPY)$</a>; <a href=\"https://ttm.financial/S/QQQ\">$QQQ(QQQ)$</a>; <a href=\"https://ttm.financial/S/TSLA\">$Tesla(TSLA)$</a>; <a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>; <a href=\"https://ttm.financial/S/NVDA\">$Nvidia(NVDA)$</a>; <a href=\"https://ttm.financial/S/AMD\">$Advanced Micro Devices(AMD)$</a> ; <a href=\"https://ttm.financial/S/VIX\">$Cboe Volatility Index(VIX)$</a> ; <a href=\"https://ttm.financial/S/AMZN\">$Amazon.com(AMZN)$</a> ;","listText":"The S&P 500 and Nasdaq fell on Thursday(July 20), weighed down by drops in Tesla and Netflix following their quarterly results.Regarding the options market, a total volume of 44,774,900 contracts was traded, up 4% from the previous trading day.Top 10 Option VolumesTop 10: <a href=\"https://ttm.financial/S/SPY\">$SPY(SPY)$</a>; <a href=\"https://ttm.financial/S/QQQ\">$QQQ(QQQ)$</a>; <a href=\"https://ttm.financial/S/TSLA\">$Tesla(TSLA)$</a>; <a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>; <a href=\"https://ttm.financial/S/NVDA\">$Nvidia(NVDA)$</a>; <a href=\"https://ttm.financial/S/AMD\">$Advanced Micro Devices(AMD)$</a> ; <a href=\"https://ttm.financial/S/VIX\">$Cboe Volatility Index(VIX)$</a> ; <a href=\"https://ttm.financial/S/AMZN\">$Amazon.com(AMZN)$</a> ;","text":"The S&P 500 and Nasdaq fell on Thursday(July 20), weighed down by drops in Tesla and Netflix following their quarterly results.Regarding the options market, a total volume of 44,774,900 contracts was traded, up 4% from the previous trading day.Top 10 Option VolumesTop 10: $SPY(SPY)$; $QQQ(QQQ)$; $Tesla(TSLA)$; $Apple(AAPL)$; $Nvidia(NVDA)$; $Advanced Micro Devices(AMD)$ ; $Cboe Volatility Index(VIX)$ ; $Amazon.com(AMZN)$ ;","images":[{"img":"https://community-static.tradeup.com/news/27725a9dc69d5e8b2dc93b7adab996f1"},{"img":"https://community-static.tradeup.com/news/2b6aca6a99d83846ef40f9d2c24721c1"},{"img":"https://community-static.tradeup.com/news/ae5488a0ce19be4cac521e9c95f9ae1e"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/200312277713072","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9964309967,"gmtCreate":1670068780759,"gmtModify":1676538298048,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&P 500 ETF(VOO)$ </a><v-v data-views=\"1\"></v-v>","listText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&P 500 ETF(VOO)$ </a><v-v data-views=\"1\"></v-v>","text":"$Vanguard S&P 500 ETF(VOO)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9964309967","isVote":1,"tweetType":1,"viewCount":2628,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9961545546,"gmtCreate":1669003269186,"gmtModify":1676538137985,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TWTR\">$Twitter(TWTR)$ </a><v-v data-views=\"1\"></v-v>","listText":"<a href=\"https://ttm.financial/S/TWTR\">$Twitter(TWTR)$ </a><v-v data-views=\"1\"></v-v>","text":"$Twitter(TWTR)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9961545546","isVote":1,"tweetType":1,"viewCount":2741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9963442895,"gmtCreate":1668742558818,"gmtModify":1676538106665,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9963442895","repostId":"2284748240","repostType":4,"isVote":1,"tweetType":1,"viewCount":2586,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9960943821,"gmtCreate":1668050822864,"gmtModify":1676538004913,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$ </a><v-v data-views=\"1\"></v-v>","listText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$ </a><v-v data-views=\"1\"></v-v>","text":"$SINGAPORE AIRLINES LTD(C6L.SI)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9960943821","isVote":1,"tweetType":1,"viewCount":2982,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9982088864,"gmtCreate":1667045848758,"gmtModify":1676537853816,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9982088864","repostId":"9986216200","repostType":1,"repost":{"id":9986216200,"gmtCreate":1666961873200,"gmtModify":1676537840246,"author":{"id":"3501196737273098","authorId":"3501196737273098","name":"Tiger_comments","avatar":"https://community-static.tradeup.com/news/227887b200e9925968650d5db4a8bfb3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3501196737273098","authorIdStr":"3501196737273098"},"themes":[],"title":"[TOPIC] FAMMG Evaporated $276.6 billion Last Night: Short/Bottom?","htmlText":"FAMMG all fell in Q3 earnings season. Yesterday, top five tech giants evaporated a total market cap of $276.6 billion.1. <a href=\"https://ttm.financial/S/GOOG\">$Google (GOOG)$</a> 's earnings report released after the bell on Tuesday, Q3 revenue and profit fell short of expectations, and the stock price fell more than 6% after the bell2. <a href=\"https://ttm.financial/S/MSFT\">$Microsoft(MSFT)$</a> revenue growth fell to a 5-year low, shares fell nearly 7% after hours3. After the bell on Wednesday, META also released a less-than-expected Q3 earnings report, and its stock price plunged nearly 25% on Thursday. So far this year, Meta's market capitalization has fallen, evaporating from a high of nearly $1 trillion to $730 billion, leaving a market capitalization o","listText":"FAMMG all fell in Q3 earnings season. Yesterday, top five tech giants evaporated a total market cap of $276.6 billion.1. <a href=\"https://ttm.financial/S/GOOG\">$Google (GOOG)$</a> 's earnings report released after the bell on Tuesday, Q3 revenue and profit fell short of expectations, and the stock price fell more than 6% after the bell2. <a href=\"https://ttm.financial/S/MSFT\">$Microsoft(MSFT)$</a> revenue growth fell to a 5-year low, shares fell nearly 7% after hours3. After the bell on Wednesday, META also released a less-than-expected Q3 earnings report, and its stock price plunged nearly 25% on Thursday. So far this year, Meta's market capitalization has fallen, evaporating from a high of nearly $1 trillion to $730 billion, leaving a market capitalization o","text":"FAMMG all fell in Q3 earnings season. Yesterday, top five tech giants evaporated a total market cap of $276.6 billion.1. $Google (GOOG)$ 's earnings report released after the bell on Tuesday, Q3 revenue and profit fell short of expectations, and the stock price fell more than 6% after the bell2. $Microsoft(MSFT)$ revenue growth fell to a 5-year low, shares fell nearly 7% after hours3. After the bell on Wednesday, META also released a less-than-expected Q3 earnings report, and its stock price plunged nearly 25% on Thursday. So far this year, Meta's market capitalization has fallen, evaporating from a high of nearly $1 trillion to $730 billion, leaving a market capitalization o","images":[{"img":"https://community-static.tradeup.com/news/3ea0d65980edac8c7f429a0c8e914e12","width":"-1","height":"-1"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986216200","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9918420655,"gmtCreate":1664435205377,"gmtModify":1676537454866,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9918420655","repostId":"2271737074","repostType":4,"repost":{"id":"2271737074","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1664406595,"share":"https://ttm.financial/m/news/2271737074?lang=en_US&edition=fundamental","pubTime":"2022-09-29 07:09","market":"us","language":"en","title":"US STOCKS-Wall Street Ends Sharply Higher as Treasury Yields Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2271737074","media":"Reuters","summary":"Apple drops on concerns about iPhone demandTreasury prices rebound after BoE decisionS&P 500 records largest one-day gain since Aug. 10Indexes: Dow +1.88%, S&P 500 +1.97%, Nasdaq +2.05%Sept 28 (Reuter","content":"<html><head></head><body><ul><li>Apple drops on concerns about iPhone demand</li><li>Treasury prices rebound after BoE decision</li><li>S&P 500 records largest one-day gain since Aug. 10</li><li>Indexes: Dow +1.88%, S&P 500 +1.97%, Nasdaq +2.05%</li></ul><p>Sept 28 (Reuters) - Wall Street ended sharply higher on Wednesday following its recent sell-off, helped by falling Treasury yields, while Apple dropped on concerns about demand for iPhones.</p><p>The S&P 500 recorded its first gain in seven sessions after closing on Tuesday at its lowest since late 2020.</p><p>Interest rate-sensitive megacaps Microsoft, Amazon and <a href=\"https://laohu8.com/S/META\">Meta Platforms</a> rallied as the yield on 10-year Treasury notes fell over 0.26 percentage point in its biggest one-day drop since 2009.</p><p>Pushing yields lower on Treasuries with maturities six months and longer, the Bank of England said it would buy long-dated British bonds in a move aimed at restoring financial stability in markets rocked globally by the fiscal policy of the new government in London.</p><p>"The yield on the two-year Treasury has gone up persistently over the course of the last several weeks, and for the first time we've seen it go down for two days in a row, and that has given equities a breather," said Art Hogan, chief market strategist at B. Riley Wealth.</p><p>Investors have been keenly listening to comments from Federal Reserve officials about the path of monetary policy, with Atlanta Fed President Raphael Bostic on Wednesday backing another 75-basis-point interest rate hike in November. The Fed will likely get borrowing costs to where they need to be by early next year, Federal Reserve Bank of Chicago President Charles Evans said.</p><p>U.S. stocks have been battered in 2022 by worries that an aggressive push by the Fed to raise borrowing costs could throw the economy into a downturn.</p><p>Apple Inc dropped 1.3% after Bloomberg reported the company is dropping plans to increase production of its new iPhones this year after an anticipated surge in demand failed to materialize.</p><p>Apple has been a relative outperformer in 2022's stock market sell-off, down about 15% in the year to date, versus the S&P 500's 22% loss.</p><p>All of the 11 S&P 500 sector indexes rose, led by a 4.4% jump in energy and a 3.2% leap in communication services .</p><p>The Dow Jones Industrial Average rose 1.88% to end at 29,683.74 points, while the S&P 500 gained 1.97% to 3,719.04. It was the S&P 500's largest one-day gain since Aug. 10.</p><p>The Nasdaq Composite jumped 2.05% to 11,051.64.</p><p>Biogen Inc surged 40% after saying its experimental Alzheimer's drug, developed with Japanese partner Eisai Co Ltd , succeeded in slowing cognitive decline.</p><p>Eli Lilly & Co, which is also developing an Alzheimer's drug, jumped 7.5%, and it was among the biggest boosts to the S&P 500 index.</p><p>Advancing issues outnumbered declining ones on the NYSE by a 5.82-to-1 ratio; on Nasdaq, a 3.66-to-1 ratio favored advancers.</p><p>The S&P 500 posted one new 52-week high and 30 new lows; the Nasdaq Composite recorded 26 new highs and 224 new lows.</p><p>Volume on U.S. exchanges was 11.7 billion shares, compared with an 11.4 billion average for the full session over the last 20 trading days.</p><p><img src=\"https://static.tigerbbs.com/da8e9a6ce881361e45c74a1b02609eaf\" tg-width=\"1080\" tg-height=\"1920\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US STOCKS-Wall Street Ends Sharply Higher as Treasury Yields Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS STOCKS-Wall Street Ends Sharply Higher as Treasury Yields Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-09-29 07:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><ul><li>Apple drops on concerns about iPhone demand</li><li>Treasury prices rebound after BoE decision</li><li>S&P 500 records largest one-day gain since Aug. 10</li><li>Indexes: Dow +1.88%, S&P 500 +1.97%, Nasdaq +2.05%</li></ul><p>Sept 28 (Reuters) - Wall Street ended sharply higher on Wednesday following its recent sell-off, helped by falling Treasury yields, while Apple dropped on concerns about demand for iPhones.</p><p>The S&P 500 recorded its first gain in seven sessions after closing on Tuesday at its lowest since late 2020.</p><p>Interest rate-sensitive megacaps Microsoft, Amazon and <a href=\"https://laohu8.com/S/META\">Meta Platforms</a> rallied as the yield on 10-year Treasury notes fell over 0.26 percentage point in its biggest one-day drop since 2009.</p><p>Pushing yields lower on Treasuries with maturities six months and longer, the Bank of England said it would buy long-dated British bonds in a move aimed at restoring financial stability in markets rocked globally by the fiscal policy of the new government in London.</p><p>"The yield on the two-year Treasury has gone up persistently over the course of the last several weeks, and for the first time we've seen it go down for two days in a row, and that has given equities a breather," said Art Hogan, chief market strategist at B. Riley Wealth.</p><p>Investors have been keenly listening to comments from Federal Reserve officials about the path of monetary policy, with Atlanta Fed President Raphael Bostic on Wednesday backing another 75-basis-point interest rate hike in November. The Fed will likely get borrowing costs to where they need to be by early next year, Federal Reserve Bank of Chicago President Charles Evans said.</p><p>U.S. stocks have been battered in 2022 by worries that an aggressive push by the Fed to raise borrowing costs could throw the economy into a downturn.</p><p>Apple Inc dropped 1.3% after Bloomberg reported the company is dropping plans to increase production of its new iPhones this year after an anticipated surge in demand failed to materialize.</p><p>Apple has been a relative outperformer in 2022's stock market sell-off, down about 15% in the year to date, versus the S&P 500's 22% loss.</p><p>All of the 11 S&P 500 sector indexes rose, led by a 4.4% jump in energy and a 3.2% leap in communication services .</p><p>The Dow Jones Industrial Average rose 1.88% to end at 29,683.74 points, while the S&P 500 gained 1.97% to 3,719.04. It was the S&P 500's largest one-day gain since Aug. 10.</p><p>The Nasdaq Composite jumped 2.05% to 11,051.64.</p><p>Biogen Inc surged 40% after saying its experimental Alzheimer's drug, developed with Japanese partner Eisai Co Ltd , succeeded in slowing cognitive decline.</p><p>Eli Lilly & Co, which is also developing an Alzheimer's drug, jumped 7.5%, and it was among the biggest boosts to the S&P 500 index.</p><p>Advancing issues outnumbered declining ones on the NYSE by a 5.82-to-1 ratio; on Nasdaq, a 3.66-to-1 ratio favored advancers.</p><p>The S&P 500 posted one new 52-week high and 30 new lows; the Nasdaq Composite recorded 26 new highs and 224 new lows.</p><p>Volume on U.S. exchanges was 11.7 billion shares, compared with an 11.4 billion average for the full session over the last 20 trading days.</p><p><img src=\"https://static.tigerbbs.com/da8e9a6ce881361e45c74a1b02609eaf\" tg-width=\"1080\" tg-height=\"1920\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2271737074","content_text":"Apple drops on concerns about iPhone demandTreasury prices rebound after BoE decisionS&P 500 records largest one-day gain since Aug. 10Indexes: Dow +1.88%, S&P 500 +1.97%, Nasdaq +2.05%Sept 28 (Reuters) - Wall Street ended sharply higher on Wednesday following its recent sell-off, helped by falling Treasury yields, while Apple dropped on concerns about demand for iPhones.The S&P 500 recorded its first gain in seven sessions after closing on Tuesday at its lowest since late 2020.Interest rate-sensitive megacaps Microsoft, Amazon and Meta Platforms rallied as the yield on 10-year Treasury notes fell over 0.26 percentage point in its biggest one-day drop since 2009.Pushing yields lower on Treasuries with maturities six months and longer, the Bank of England said it would buy long-dated British bonds in a move aimed at restoring financial stability in markets rocked globally by the fiscal policy of the new government in London.\"The yield on the two-year Treasury has gone up persistently over the course of the last several weeks, and for the first time we've seen it go down for two days in a row, and that has given equities a breather,\" said Art Hogan, chief market strategist at B. Riley Wealth.Investors have been keenly listening to comments from Federal Reserve officials about the path of monetary policy, with Atlanta Fed President Raphael Bostic on Wednesday backing another 75-basis-point interest rate hike in November. The Fed will likely get borrowing costs to where they need to be by early next year, Federal Reserve Bank of Chicago President Charles Evans said.U.S. stocks have been battered in 2022 by worries that an aggressive push by the Fed to raise borrowing costs could throw the economy into a downturn.Apple Inc dropped 1.3% after Bloomberg reported the company is dropping plans to increase production of its new iPhones this year after an anticipated surge in demand failed to materialize.Apple has been a relative outperformer in 2022's stock market sell-off, down about 15% in the year to date, versus the S&P 500's 22% loss.All of the 11 S&P 500 sector indexes rose, led by a 4.4% jump in energy and a 3.2% leap in communication services .The Dow Jones Industrial Average rose 1.88% to end at 29,683.74 points, while the S&P 500 gained 1.97% to 3,719.04. It was the S&P 500's largest one-day gain since Aug. 10.The Nasdaq Composite jumped 2.05% to 11,051.64.Biogen Inc surged 40% after saying its experimental Alzheimer's drug, developed with Japanese partner Eisai Co Ltd , succeeded in slowing cognitive decline.Eli Lilly & Co, which is also developing an Alzheimer's drug, jumped 7.5%, and it was among the biggest boosts to the S&P 500 index.Advancing issues outnumbered declining ones on the NYSE by a 5.82-to-1 ratio; on Nasdaq, a 3.66-to-1 ratio favored advancers.The S&P 500 posted one new 52-week high and 30 new lows; the Nasdaq Composite recorded 26 new highs and 224 new lows.Volume on U.S. exchanges was 11.7 billion shares, compared with an 11.4 billion average for the full session over the last 20 trading days.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":3178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9999279147,"gmtCreate":1660541759291,"gmtModify":1676533557786,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9999279147","repostId":"1164245640","repostType":4,"repost":{"id":"1164245640","kind":"news","pubTimestamp":1660519300,"share":"https://ttm.financial/m/news/1164245640?lang=en_US&edition=fundamental","pubTime":"2022-08-15 07:21","market":"us","language":"en","title":"Fed Minutes May Reveal Inclinations on Size of Next Rate Hike","url":"https://stock-news.laohu8.com/highlight/detail?id=1164245640","media":"Bloomberg","summary":"Bets on next move have swung back and forth on jobs, inflationOfficials, investors out of step on le","content":"<div>\n<p>Bets on next move have swung back and forth on jobs, inflationOfficials, investors out of step on length of tightening cycleAn account of the debate at the Federal Reserve’s July policy meeting, set ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-08-14/fed-minutes-may-reveal-inclinations-on-size-of-next-rate-hike\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fed Minutes May Reveal Inclinations on Size of Next Rate Hike</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFed Minutes May Reveal Inclinations on Size of Next Rate Hike\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-15 07:21 GMT+8 <a href=https://www.bloomberg.com/news/articles/2022-08-14/fed-minutes-may-reveal-inclinations-on-size-of-next-rate-hike><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bets on next move have swung back and forth on jobs, inflationOfficials, investors out of step on length of tightening cycleAn account of the debate at the Federal Reserve’s July policy meeting, set ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-08-14/fed-minutes-may-reveal-inclinations-on-size-of-next-rate-hike\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.bloomberg.com/news/articles/2022-08-14/fed-minutes-may-reveal-inclinations-on-size-of-next-rate-hike","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164245640","content_text":"Bets on next move have swung back and forth on jobs, inflationOfficials, investors out of step on length of tightening cycleAn account of the debate at the Federal Reserve’s July policy meeting, set to be published after two weeks of whiplash on Wall Street, will probably offer clues as to what would push the central bank to go big with tightening yet again in September.Fed officials’ decision at their July 26-27 gathering to raise their benchmark interest rate by three quarters of a percentage point for a second straight month marked the fastest pace of tightening since the early 1980s. And since then, betting in financial markets on the size of the next move in September has swung between 50 and 75 basis points on reports alternately showing a stronger-than-expected labor market and inflation below forecasts.The minutes, due out at 2 p.m. in Washington on Wednesday, probably won’t settle the matter. But they could indicate what kind of data Fed officials would need to see to favor another “unusually large” increase -- which Chair Jerome Powell, at a press conference following the July meeting, said could be on the table for the Sept. 20-21 gathering as well.“If there is going to be new information, it would be around the idea of: Are further rate hikes likely to be of smaller incremental size, or is the door really open to something larger?” said Michael Gapen, head of US economics at Bank of America in New York.“Cost-benefit analysis shifts in the direction of smaller hikes -- and the inflation data probably helped them out that way -- but you get another strong labor-market report and it might be hard for them not to go 75” basis points again, Gapen said.Fed officials who have spoken since the July meeting have pushed back against any perception that they’d be pivoting away from tightening any time soon. They’ve made it clear that curbing the hottest inflation in four decades is their top priority.The July jobs data, published by the Labor Department on Aug. 5, showed companies added 528,000 employees to payrolls last month, more than double what forecasters were expecting, and the unemployment rate ticked down to 3.5%, matching the pre-pandemic low. That report prompted investors to bet on a third straight 75-basis-point hike.But the department’s Aug. 10 readout on consumer pricesshowedthey rose 8.5% in the 12 months through July, down from the 9.1% increase in the year to June that had marked the highest inflation rate since 1981. That was enough to largely unwind previous bets, and investors are now assigning similar odds to a half-point or a three-quarter-point increase, according to prices of futures contracts tied to the Fed’s benchmark rate.The central bank has been raising rates since March. Fed officials have increasingly admitted they feel like they were too slow to begin doing so, which prompted them to go first from quarter-, then to half-, and finally to three-quarter-point hikes to catch up as inflation worsened.Following the July increase, the target range for the benchmark rate stands at 2.25% to 2.5%, a level many officials feel is roughly “neutral” for the economy.Market Sees Fed Reversing Course Early Next YearInvestors price rate cuts for 2023 over objections from Fed officials“We’re going to be making decisions meeting by meeting,” Powell told reporters at the July 27 press conference. “We think it’s time to just go to a meeting-by-meeting basis and not provide the kind of clear guidance that we had provided on the way to neutral,” he said.Divining MoveAugust numbers on jobs and consumer prices are due out before the September meeting, and will probably be critical in shaping market expectations ahead of that decision.In public commentary since the July meeting, Fed officials haveemphasizedthey are far away from declaring victory on inflation, and have asserted that rate hikes will probably continue into next year, after which rates will remain elevated for some time.Investors, on the other hand, are betting the central bank will start reversing course with rate cuts by mid-2023.“We’re trying to look for any clues to gain knowledge on what they are really going to feel comfortable with on the inflation front,” said Tom Porcelli, chief US economist at RBC Capital Markets in New York. Any information the minutes can provide on “what would be a comfortable down-shift in inflation, and how long they would want to see it go on for,” will be read closely, he said.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2491,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9907913051,"gmtCreate":1660124899876,"gmtModify":1703478164553,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9907913051","repostId":"1151301230","repostType":4,"repost":{"id":"1151301230","kind":"news","pubTimestamp":1660122870,"share":"https://ttm.financial/m/news/1151301230?lang=en_US&edition=fundamental","pubTime":"2022-08-10 17:14","market":"us","language":"en","title":"AstraZeneca’s Stock Is Well Suited for Long-Term Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1151301230","media":"TipRanks","summary":"Story HighlightsThe COVID-19 pandemic has brought pharma stocks on the radar of investors – but does","content":"<div>\n<p>Story HighlightsThe COVID-19 pandemic has brought pharma stocks on the radar of investors – but does Astra Zeneca have what it takes to deliver long-term?Pharma giant AstraZeneca(GB:AZN)became a ...</p>\n\n<a href=\"https://www.tipranks.com/news/article/astrazenecas-stock-is-well-suited-for-long-term-growth/\">Source Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca’s Stock Is Well Suited for Long-Term Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca’s Stock Is Well Suited for Long-Term Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-10 17:14 GMT+8 <a href=https://www.tipranks.com/news/article/astrazenecas-stock-is-well-suited-for-long-term-growth/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Story HighlightsThe COVID-19 pandemic has brought pharma stocks on the radar of investors – but does Astra Zeneca have what it takes to deliver long-term?Pharma giant AstraZeneca(GB:AZN)became a ...</p>\n\n<a href=\"https://www.tipranks.com/news/article/astrazenecas-stock-is-well-suited-for-long-term-growth/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"https://www.tipranks.com/news/article/astrazenecas-stock-is-well-suited-for-long-term-growth/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151301230","content_text":"Story HighlightsThe COVID-19 pandemic has brought pharma stocks on the radar of investors – but does Astra Zeneca have what it takes to deliver long-term?Pharma giant AstraZeneca(GB:AZN)became a globally famous name thanks to its COVID vaccine and is among the biggest companies in the FTSE 100 – not to mention the fact that its stock has generated around 60% returns in the last three years.Pharma stocks are primarily influenced by the revenue generated by the companies’ drugs. AZN has a strong pipeline of drugs ahead, which could lead to a substantial push in revenues and stock price.First-half results: Robust growthThe company recently reported its half-yearly results for 2022 with solid revenue numbers. The total revenue for the group increased by 48% to $22.2 billion. The revenues were mainly driven by the biopharmaceuticals segment, which contributed around 47% of the total revenues.Revenues grew by 31% to $10.4 billion because of solid sales of Farxiga, a type 2 diabetes drug, and other COVID-19 medicines.The top-line growth led to a solid increase in earnings per share (EPS). The core EPS was reported at $3.61, which was 44% higher than the previous year. The EPS benefited from a core tax rate of 15%. For the second half of 2022, the company expects the tax rate to be in the range of 18–22%.AZN has increased its full-year 2022 guidance for revenue, considering strong results across the various business segments. Revenue is now expected to grow by a low twenties percentage. Core EPS is expected to rise by a percentage in the mid-to-high twenties.A diverse and solid pipelineThe company is betting big on its revenue because of a solid pipeline ahead. The company’s pipeline is spread across various stages of clinical trials. It has a total of 184 projects in the pipeline and 17 new molecular entities in late-stage pipeline.Last month, investors welcomed the news that its asthma drug Tezspire and autoimmune drug Ultomiris had received EU marketing approval. Also, its breast cancer drug Enhertu got a priority review by the U.S. FDA.Enhertu is already approved by the EU for expanded use.The pipeline shows that the company will continue to be a strong player in the pharma industry for many years to come.View from the CityAccording to TipRanks’ analyst rating consensus, AZN stock has a Strong Buy rating from 13 analysts. It includes 10 Buy and three Hold recommendations.It has an average price target of 11,184.17p, which represents a 3.04% change in the price from the level of 10,766p. The price has a low and high forecast of 15,300p and 1,010p, respectively.ConclusionThe AZN stock is a gem for investors who prefer stability over fast and high growth.The company’s guidance numbers and drug pipeline are enough to drive long-term growth in revenues, which will be reflected in the share prices as well.","news_type":1,"symbols_score_info":{"AZN":0.9}},"isVote":1,"tweetType":1,"viewCount":2373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9908797484,"gmtCreate":1659433653551,"gmtModify":1705980315431,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9908797484","repostId":"9908795173","repostType":1,"repost":{"id":9908795173,"gmtCreate":1659433188195,"gmtModify":1705980310909,"author":{"id":"4119381554926662","authorId":"4119381554926662","name":"greeny9451","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4119381554926662","authorIdStr":"4119381554926662"},"themes":[],"htmlText":"Down then up Living costs mortgage pressure increasing, house equity reducing strongly covid wave potential, consumers nervous losing confidence , oil to rise again building companies failing supply chain issues for many companies to many pressures in world at present more risks i feel so i think reset first slight up end 2022 strong up 2023 at back end when inflation normalises oil back to 66 usd i think current rally bit of hope on past earnings but i think market will soon realise future performance across most sectors more difficult to grow for next 12 months ie savings people built up during lockdown now falling to finance living costs mortgage people may sell equity use cash tiget far aheadcin in mortgage or kids education funding so liquidity in mar","listText":"Down then up Living costs mortgage pressure increasing, house equity reducing strongly covid wave potential, consumers nervous losing confidence , oil to rise again building companies failing supply chain issues for many companies to many pressures in world at present more risks i feel so i think reset first slight up end 2022 strong up 2023 at back end when inflation normalises oil back to 66 usd i think current rally bit of hope on past earnings but i think market will soon realise future performance across most sectors more difficult to grow for next 12 months ie savings people built up during lockdown now falling to finance living costs mortgage people may sell equity use cash tiget far aheadcin in mortgage or kids education funding so liquidity in mar","text":"Down then up Living costs mortgage pressure increasing, house equity reducing strongly covid wave potential, consumers nervous losing confidence , oil to rise again building companies failing supply chain issues for many companies to many pressures in world at present more risks i feel so i think reset first slight up end 2022 strong up 2023 at back end when inflation normalises oil back to 66 usd i think current rally bit of hope on past earnings but i think market will soon realise future performance across most sectors more difficult to grow for next 12 months ie savings people built up during lockdown now falling to finance living costs mortgage people may sell equity use cash tiget far aheadcin in mortgage or kids education funding so liquidity in mar","images":[],"top":1,"highlighted":2,"essential":2,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9908795173","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9908997634,"gmtCreate":1659310982228,"gmtModify":1676536283712,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9908997634","repostId":"2255525529","repostType":4,"repost":{"id":"2255525529","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1659232645,"share":"https://ttm.financial/m/news/2255525529?lang=en_US&edition=fundamental","pubTime":"2022-07-31 09:57","market":"us","language":"en","title":"Boeing Makes New Offer to St. Louis-Area Workers, Delaying Strike","url":"https://stock-news.laohu8.com/highlight/detail?id=2255525529","media":"Dow Jones","summary":"Workers at three Boeing Co. defense manufacturing plants will vote Wednesday on a modified labor con","content":"<html><head></head><body><p>Workers at three Boeing Co. defense manufacturing plants will vote Wednesday on a modified labor contract proposal, temporarily avoiding a strike that was slated to start as soon as Monday.</p><p>The International Association of Machinists and Aerospace Workers said that the aerospace company made a new contract offer after an overnight bargaining session between the two sides. About 2,500 members of the union's District 837 work at three St. Louis-area Boeing plants that make weapons and military aircraft including the F-15 combat jet, the T-7A trainer and the MQ-25 refueling drone.</p><p>Boeing said it was hopeful that workers will accept the new offer, which addressed issues employees had previously raised during negotiations. The contract dispute has largely focused on retirement benefits for the St. Louis-area workers.</p><p>The company's proposed three-year contract offers new workers an $8,000 lump-sum payment and scraps earlier plans to cut company contributions to employees' 401(k) savings plans. A strike could start Thursday if employees reject the proposal.</p><p>Boeing on Wednesday said its second-quarter results showed it was making progress in stabilizing its operations after a series of quality issues dragged down results in its commercial aviation business. The results included a series of one-time charges, including some tied to cost overruns in its defense business.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boeing Makes New Offer to St. Louis-Area Workers, Delaying Strike</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoeing Makes New Offer to St. Louis-Area Workers, Delaying Strike\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-07-31 09:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Workers at three Boeing Co. defense manufacturing plants will vote Wednesday on a modified labor contract proposal, temporarily avoiding a strike that was slated to start as soon as Monday.</p><p>The International Association of Machinists and Aerospace Workers said that the aerospace company made a new contract offer after an overnight bargaining session between the two sides. About 2,500 members of the union's District 837 work at three St. Louis-area Boeing plants that make weapons and military aircraft including the F-15 combat jet, the T-7A trainer and the MQ-25 refueling drone.</p><p>Boeing said it was hopeful that workers will accept the new offer, which addressed issues employees had previously raised during negotiations. The contract dispute has largely focused on retirement benefits for the St. Louis-area workers.</p><p>The company's proposed three-year contract offers new workers an $8,000 lump-sum payment and scraps earlier plans to cut company contributions to employees' 401(k) savings plans. A strike could start Thursday if employees reject the proposal.</p><p>Boeing on Wednesday said its second-quarter results showed it was making progress in stabilizing its operations after a series of quality issues dragged down results in its commercial aviation business. The results included a series of one-time charges, including some tied to cost overruns in its defense business.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BA":"波音"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2255525529","content_text":"Workers at three Boeing Co. defense manufacturing plants will vote Wednesday on a modified labor contract proposal, temporarily avoiding a strike that was slated to start as soon as Monday.The International Association of Machinists and Aerospace Workers said that the aerospace company made a new contract offer after an overnight bargaining session between the two sides. About 2,500 members of the union's District 837 work at three St. Louis-area Boeing plants that make weapons and military aircraft including the F-15 combat jet, the T-7A trainer and the MQ-25 refueling drone.Boeing said it was hopeful that workers will accept the new offer, which addressed issues employees had previously raised during negotiations. The contract dispute has largely focused on retirement benefits for the St. Louis-area workers.The company's proposed three-year contract offers new workers an $8,000 lump-sum payment and scraps earlier plans to cut company contributions to employees' 401(k) savings plans. A strike could start Thursday if employees reject the proposal.Boeing on Wednesday said its second-quarter results showed it was making progress in stabilizing its operations after a series of quality issues dragged down results in its commercial aviation business. The results included a series of one-time charges, including some tied to cost overruns in its defense business.","news_type":1,"symbols_score_info":{"BA":1}},"isVote":1,"tweetType":1,"viewCount":1180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9900403007,"gmtCreate":1658743416409,"gmtModify":1676536200401,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9900403007","repostId":"9900400163","repostType":1,"repost":{"id":9900400163,"gmtCreate":1658743037578,"gmtModify":1676536200385,"author":{"id":"3479274802455671","authorId":"3479274802455671","name":"frosti","avatar":"https://static.tigerbbs.com/8d59e7c960eef6f97257cc799768d81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479274802455671","authorIdStr":"3479274802455671"},"themes":[],"title":"Snap Crackles and Pops After Disappointing Investor Update","htmlText":"The company reported its slowest revenue growth rate in years.Snapchat parentSnap(SNAP-39.08%)reported fiscal 2022 second-quarter earnings after the markets closed on Thursday, July 21. The social media company disappointed investors by reporting slower-than-expected revenue growth. Snap had warned the market several weeks earlier that its second quarter was evolving worse than expected, but these results on July 21 managed to disappoint already lowered expectations.The stock was down as much as 38% on the day following the release, a dramatic fall for the once-loved business. Let's dig into the details of that Q2 report and decipher what is causing the poor performance.Snap manages to disappoint already lowered expectationsSnap had first forecasted revenue growth between 20% and 25% for i","listText":"The company reported its slowest revenue growth rate in years.Snapchat parentSnap(SNAP-39.08%)reported fiscal 2022 second-quarter earnings after the markets closed on Thursday, July 21. The social media company disappointed investors by reporting slower-than-expected revenue growth. Snap had warned the market several weeks earlier that its second quarter was evolving worse than expected, but these results on July 21 managed to disappoint already lowered expectations.The stock was down as much as 38% on the day following the release, a dramatic fall for the once-loved business. Let's dig into the details of that Q2 report and decipher what is causing the poor performance.Snap manages to disappoint already lowered expectationsSnap had first forecasted revenue growth between 20% and 25% for i","text":"The company reported its slowest revenue growth rate in years.Snapchat parentSnap(SNAP-39.08%)reported fiscal 2022 second-quarter earnings after the markets closed on Thursday, July 21. The social media company disappointed investors by reporting slower-than-expected revenue growth. Snap had warned the market several weeks earlier that its second quarter was evolving worse than expected, but these results on July 21 managed to disappoint already lowered expectations.The stock was down as much as 38% on the day following the release, a dramatic fall for the once-loved business. Let's dig into the details of that Q2 report and decipher what is causing the poor performance.Snap manages to disappoint already lowered expectationsSnap had first forecasted revenue growth between 20% and 25% for i","images":[{"img":"https://community-static.tradeup.com/news/28ef11b538fec0af901c5db6e96ad114","width":"-1","height":"-1"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9900400163","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9074312794,"gmtCreate":1658295073218,"gmtModify":1676536136903,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094293265127660","authorIdStr":"4094293265127660"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9074312794","repostId":"1151508320","repostType":4,"repost":{"id":"1151508320","kind":"news","pubTimestamp":1658289497,"share":"https://ttm.financial/m/news/1151508320?lang=en_US&edition=fundamental","pubTime":"2022-07-20 11:58","market":"us","language":"en","title":"Palantir: Possibly The Buy Of The Decade Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1151508320","media":"Seeking Alpha","summary":"SummaryPalantir has been one of the worst-hit stocks since the growth meltdown began last year.While","content":"<html><head></head><body><p><b>Summary</b></p><ul><li>Palantir has been one of the worst-hit stocks since the growth meltdown began last year.</li><li>While dilution, SBC, lack of profitability, and a high valuation are valid concerns, they are probably transitory factors.</li><li>The market has been a voting machine for Palantir's stock recently, but it should price the company's shares much higher long term.</li></ul><p>Palantir Technologies Inc. (NYSE:PLTR) is one of the most controversial companies. The company's market cap is floating at around $18 billion, more than ten times TTM sales. Moreover, the company is infamous for its dilution and has never shown a net profit in a single quarter. Therefore, it is no surprise that since the growth meltdown began last year, Palantir has been one of the worst-hit stocks. The company experienced an epic drop of 80% from peak to trough, but the share price has begun to recover.</p><p><b>PLTR 1-Year</b></p><p><img src=\"https://static.tigerbbs.com/9de65d4b86e4ec1d262d3162399e05b7\" tg-width=\"640\" tg-height=\"676\" referrerpolicy=\"no-referrer\"/></p><p>PLTR (StockCharts.com)</p><p>Benjamin Graham may have said it best - "In the short term, the market is a voting machine, but in the long run, it is a weighing machine." Mr. Graham was a brilliant investor, and the saying applies exceptionally well to Palantir, in my view. The market seemed crazy about Palantir when the stock was at $20 or $30, but is not fond of Palantir these days. The stock was severely diluted after its IPO, and the criticisms of stock-based compensation ("SBC") continue today. Moreover, growth and high multiple stocks are not as popular as they were throughout most of 2021, and with a possible recession approaching, the market is voting "No" on Palantir.</p><p>However, let's weigh Palantir's stock instead of voting for it. Dilution and SBC compensation are common phenomena with IPOs, and Palantir is not an exception. Let's not look at past sales, but let us focus on the company's revenue growth and earning potential. Additionally, let's consider Palantir's unique, leading, and dominant market position and how it could impact future growth prospects and profitability potential. Moreover, Palantir's growth runway is massive, and its profitability potential is vast, making the stock possibly one of the best buys for the next decade.</p><p><b>Palantir - The Government's Favorite Contractor</b></p><p>One of Palantir's most unique facets is its dominant position as a government contractor. The company provides software solutions through its Gotham program to numerous government agencies. Some of Palantir's government clients include the U.S. military, intelligence, and police. More specifically, the FBI, DOD, CIA, NSA, and many other agencies use Palantir's linked databases,data mining solutions, analysis software, and much more. Furthermore, Palantir services the NHS, FDA, and other agencies. While Palantir is growing its corporate business aggressively, it still derived most of its revenues (54%) from government contracts last quarter. Advantageously, Palantir gets a substantial portion of its revenues from the government as the government is famous for its loose spending policies. Moreover, the company should continue growing government revenues, and even when a recession comes, the government will continue its spending.</p><p><b>It's All About Growth - For Now</b></p><p>I hear a lot of complaints that Palantir is not profitable, but Palantir does not need to be profitable. The company is growing at more than 30%.</p><p><img src=\"https://static.tigerbbs.com/86703bab0eb031120a21a04070660751\" tg-width=\"640\" tg-height=\"318\" referrerpolicy=\"no-referrer\"/></p><p>Q1 Highlights (investors.palantir.com)</p><p>Palantir's growth metrics are tremendous. 31% YoY revenue growth, 54% YoY commercial revenue growth, 136% YoY U.S. commercial revenue growth, and 86% YoY customer count growth. While the company's government business remains its anchor, we see Palantir growing its commercial business aggressively now. Moreover, we should continue seeing robust growth from the government and corporate clients as the company moves on. For full-year 2022, the company expects to show an adjusted operating margin of approximately 27% and anticipates providing30% annual growthor greater through 2025.</p><p><b>Be Patient - Profitability Will Come</b></p><p>Palantir is a high-growth company. Therefore, there is no need for it to be profitable right now. The company needs to focus on growing operations, increasing market share, and setting up future profitability potential. However, when it's time, Palantir should be exceptionally profitable.</p><p><b>Statement of Operations</b></p><p><img src=\"https://static.tigerbbs.com/c68e8a7494948e5f170dc64534d1921a\" tg-width=\"640\" tg-height=\"663\" referrerpolicy=\"no-referrer\"/></p><p>Statement of Operations (investors.palantir.com)</p><p>Last quarter, the company's gross profit increased by32% YoY. At the same time, Palantir's operating expenses increased by only 2.6% YoY. Therefore, the operating loss last quarter was much narrower than last year's, just $39.4 million vs. $114 million one year ago. Moreover, Palantir's gross margin came in at a whopping 78.6% the previous quarter, even higher than the 78.3% from one year ago. Thus, we see Palantir is growing increasingly profitable. As the company's gross profit continues to increase, it will start outweighing the company's operating expenses significantly, leading to substantial increases in operating income, net profit, and EPS.</p><p><b>Dilution - Not a Problem Anymore</b></p><p>We see that Palantir's share count rose by about 11% YoY. Therefore, Palantir is still diluting, but not nearly as much as it did when the company initially went public. Palantir went public with only about476 million shares. However, the company has more than 2 billion shares outstanding now. Yet, much of the dilation occurred early, essentially right after the company went public. Roughly six months after going public, the company already had nearly1.8 billion shares. Since then, SBC expenses have been declining significantly and are likely to continue falling as the company advances. Additionally, increased SBC is a common phenomenon with IPOs and is not a Palantir-isolated phenomenon.</p><p><b>SBS Expenses</b></p><p><img src=\"https://static.tigerbbs.com/5f9e8cbaa81a63e7986e0b033c550680\" tg-width=\"640\" tg-height=\"185\" referrerpolicy=\"no-referrer\"/></p><p>SBS Expenses (investors.palantir.com)</p><p>We see that, despite significantly higher revenues and income, SBC is down by about 23% YoY. This dynamic implies that the trend of lower SBC expenses should continue. Also, if we factor out the SBC expenses, we see that Palantir should become remarkably profitable. Minus SBC, the company's cost of revenue was only about<i>$82.8 million</i>, implying a gross margin of nearly 82% for Palantir. Minus SBC, Palantir's operating income would have been around<i>$110 million</i> last quarter, illustrating an operating margin of approximately 25%.</p><p>The company would have even recorded a small net income of about<i>$10 million</i> once SBC expenses are removed from the equation. The company reported an adjusted EPS of $0.02, illustrating that the company can be profitable right now, even while growing YoY revenues at more than 30%. Therefore, we see that Palantir has the potential to become increasingly prosperous. As the company's revenues and gross profit continue to rise, its operating expenses should increase modestly, and the SBC should continue declining significantly in proportion to the company's revenues. Thus, Palantir's profitability metrics should improve dramatically in the coming years.</p><p><b>Palantir - May Be Recession Proof</b></p><p>There's much concern about the upcoming recession. However, Palantir is in a unique position, as much of the company's revenues come from government contracts. The company's corporate clients are also not likely to reduce their reliance on Palantir's services, as the company provides essential solutions relating to data analytics, cybersecurity, and other critical aspects. Therefore, even in a recession, Palantir's growth should continue increasing, making it one of the best long-term buys in the market right now.</p><p><b>A Closer Look At Palantir's Valuation</b></p><p>Palantir should deliver roughly $2.6 billion in revenues next year, placing its forward P/S multiple at approximately 7. However, Palantir is a dominant market-leading high-growth company with remarkable profitability potential. Recently, the stock got voted down to a 5x forward sales multiple, when the stock fell down to $6. Now at $9 Palantir is trading at about 7 times forward sales, but it may trade at a significantly higher sales multiple down the line. Many companies with far less growth potential sell at significantly higher sales multiples.</p><p><b>Therefore, here's how Palantir's financials could look like as the company advances:</b></p><table><tbody><tr><td><b>Year</b></td><td><b>2022</b></td><td><b>2023</b></td><td><b>2024</b></td><td><b>2025</b></td><td><b>2026</b></td><td><b>2027</b></td></tr><tr><td>Revenue $</td><td>2b</td><td>2.6b</td><td>3.4b</td><td>4.4b</td><td>5.7b</td><td>7.3b</td></tr><tr><td>Revenue growth</td><td>30%</td><td>30%</td><td>30%</td><td>30%</td><td>28%</td><td>25%</td></tr><tr><td>Forward P/S ratio</td><td>7</td><td>8</td><td>9</td><td>9</td><td>8</td><td>8</td></tr><tr><td>Price</td><td>$9</td><td>$14</td><td>$21</td><td>$27</td><td>$32</td><td>$40</td></tr></tbody></table><p>Source: The Financial Prophet</p><p>Utilizing the company's projected 30% growth rate through 2025 and a slight drop-off through 2027 gets us to approximately <i>$7.3 billion</i> in revenues in 2027. The 7-9 times forward sales multiple projections are not high considering Palantir's robust growth and substantial profitability potential. Microsoft (MSFT), a software company with much slower growth, trades at about eight times forward sales. Nvidia (NVDA), a growth company with significantly slower growth, trades at approximately 12 times forward sales projections. Moreover, many other growth companies are trading at substantially higher multiples than ten times sales.</p><p>Palantir could command a P/S multiple of 7-9 or significantly higher in the coming years, possibly making the stock one of the best buys for the next decade. Therefore, the market will probably start weighing the company's stock instead of voting for it in the coming years, and Palantir's share price will likely advance much higher.</p><p><b>Risks To Palantir</b></p><p>Despite my bullish outlook for Palantir, market participants should consider several potential risks associated with this investment. While the growth story is strong at Palantir, shares are not cheap by traditional metrics. Furthermore, the company's earnings are still minimal and may not increase as much as I envision. Moreover, if the company's growth picture were to turn less bullish, the stock could head in the wrong direction. For instance, if Palantir lost favor with the government or had a data breach, the stock could experience a notable decline. Please consider these and other risks carefully before investing in Palantir.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir: Possibly The Buy Of The Decade Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir: Possibly The Buy Of The Decade Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-07-20 11:58 GMT+8 <a href=https://seekingalpha.com/article/4524288-palantir-possibly-the-buy-of-the-decade-now><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryPalantir has been one of the worst-hit stocks since the growth meltdown began last year.While dilution, SBC, lack of profitability, and a high valuation are valid concerns, they are probably ...</p>\n\n<a href=\"https://seekingalpha.com/article/4524288-palantir-possibly-the-buy-of-the-decade-now\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4524288-palantir-possibly-the-buy-of-the-decade-now","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151508320","content_text":"SummaryPalantir has been one of the worst-hit stocks since the growth meltdown began last year.While dilution, SBC, lack of profitability, and a high valuation are valid concerns, they are probably transitory factors.The market has been a voting machine for Palantir's stock recently, but it should price the company's shares much higher long term.Palantir Technologies Inc. (NYSE:PLTR) is one of the most controversial companies. The company's market cap is floating at around $18 billion, more than ten times TTM sales. Moreover, the company is infamous for its dilution and has never shown a net profit in a single quarter. Therefore, it is no surprise that since the growth meltdown began last year, Palantir has been one of the worst-hit stocks. The company experienced an epic drop of 80% from peak to trough, but the share price has begun to recover.PLTR 1-YearPLTR (StockCharts.com)Benjamin Graham may have said it best - \"In the short term, the market is a voting machine, but in the long run, it is a weighing machine.\" Mr. Graham was a brilliant investor, and the saying applies exceptionally well to Palantir, in my view. The market seemed crazy about Palantir when the stock was at $20 or $30, but is not fond of Palantir these days. The stock was severely diluted after its IPO, and the criticisms of stock-based compensation (\"SBC\") continue today. Moreover, growth and high multiple stocks are not as popular as they were throughout most of 2021, and with a possible recession approaching, the market is voting \"No\" on Palantir.However, let's weigh Palantir's stock instead of voting for it. Dilution and SBC compensation are common phenomena with IPOs, and Palantir is not an exception. Let's not look at past sales, but let us focus on the company's revenue growth and earning potential. Additionally, let's consider Palantir's unique, leading, and dominant market position and how it could impact future growth prospects and profitability potential. Moreover, Palantir's growth runway is massive, and its profitability potential is vast, making the stock possibly one of the best buys for the next decade.Palantir - The Government's Favorite ContractorOne of Palantir's most unique facets is its dominant position as a government contractor. The company provides software solutions through its Gotham program to numerous government agencies. Some of Palantir's government clients include the U.S. military, intelligence, and police. More specifically, the FBI, DOD, CIA, NSA, and many other agencies use Palantir's linked databases,data mining solutions, analysis software, and much more. Furthermore, Palantir services the NHS, FDA, and other agencies. While Palantir is growing its corporate business aggressively, it still derived most of its revenues (54%) from government contracts last quarter. Advantageously, Palantir gets a substantial portion of its revenues from the government as the government is famous for its loose spending policies. Moreover, the company should continue growing government revenues, and even when a recession comes, the government will continue its spending.It's All About Growth - For NowI hear a lot of complaints that Palantir is not profitable, but Palantir does not need to be profitable. The company is growing at more than 30%.Q1 Highlights (investors.palantir.com)Palantir's growth metrics are tremendous. 31% YoY revenue growth, 54% YoY commercial revenue growth, 136% YoY U.S. commercial revenue growth, and 86% YoY customer count growth. While the company's government business remains its anchor, we see Palantir growing its commercial business aggressively now. Moreover, we should continue seeing robust growth from the government and corporate clients as the company moves on. For full-year 2022, the company expects to show an adjusted operating margin of approximately 27% and anticipates providing30% annual growthor greater through 2025.Be Patient - Profitability Will ComePalantir is a high-growth company. Therefore, there is no need for it to be profitable right now. The company needs to focus on growing operations, increasing market share, and setting up future profitability potential. However, when it's time, Palantir should be exceptionally profitable.Statement of OperationsStatement of Operations (investors.palantir.com)Last quarter, the company's gross profit increased by32% YoY. At the same time, Palantir's operating expenses increased by only 2.6% YoY. Therefore, the operating loss last quarter was much narrower than last year's, just $39.4 million vs. $114 million one year ago. Moreover, Palantir's gross margin came in at a whopping 78.6% the previous quarter, even higher than the 78.3% from one year ago. Thus, we see Palantir is growing increasingly profitable. As the company's gross profit continues to increase, it will start outweighing the company's operating expenses significantly, leading to substantial increases in operating income, net profit, and EPS.Dilution - Not a Problem AnymoreWe see that Palantir's share count rose by about 11% YoY. Therefore, Palantir is still diluting, but not nearly as much as it did when the company initially went public. Palantir went public with only about476 million shares. However, the company has more than 2 billion shares outstanding now. Yet, much of the dilation occurred early, essentially right after the company went public. Roughly six months after going public, the company already had nearly1.8 billion shares. Since then, SBC expenses have been declining significantly and are likely to continue falling as the company advances. Additionally, increased SBC is a common phenomenon with IPOs and is not a Palantir-isolated phenomenon.SBS ExpensesSBS Expenses (investors.palantir.com)We see that, despite significantly higher revenues and income, SBC is down by about 23% YoY. This dynamic implies that the trend of lower SBC expenses should continue. Also, if we factor out the SBC expenses, we see that Palantir should become remarkably profitable. Minus SBC, the company's cost of revenue was only about$82.8 million, implying a gross margin of nearly 82% for Palantir. Minus SBC, Palantir's operating income would have been around$110 million last quarter, illustrating an operating margin of approximately 25%.The company would have even recorded a small net income of about$10 million once SBC expenses are removed from the equation. The company reported an adjusted EPS of $0.02, illustrating that the company can be profitable right now, even while growing YoY revenues at more than 30%. Therefore, we see that Palantir has the potential to become increasingly prosperous. As the company's revenues and gross profit continue to rise, its operating expenses should increase modestly, and the SBC should continue declining significantly in proportion to the company's revenues. Thus, Palantir's profitability metrics should improve dramatically in the coming years.Palantir - May Be Recession ProofThere's much concern about the upcoming recession. However, Palantir is in a unique position, as much of the company's revenues come from government contracts. The company's corporate clients are also not likely to reduce their reliance on Palantir's services, as the company provides essential solutions relating to data analytics, cybersecurity, and other critical aspects. Therefore, even in a recession, Palantir's growth should continue increasing, making it one of the best long-term buys in the market right now.A Closer Look At Palantir's ValuationPalantir should deliver roughly $2.6 billion in revenues next year, placing its forward P/S multiple at approximately 7. However, Palantir is a dominant market-leading high-growth company with remarkable profitability potential. Recently, the stock got voted down to a 5x forward sales multiple, when the stock fell down to $6. Now at $9 Palantir is trading at about 7 times forward sales, but it may trade at a significantly higher sales multiple down the line. Many companies with far less growth potential sell at significantly higher sales multiples.Therefore, here's how Palantir's financials could look like as the company advances:Year202220232024202520262027Revenue $2b2.6b3.4b4.4b5.7b7.3bRevenue growth30%30%30%30%28%25%Forward P/S ratio789988Price$9$14$21$27$32$40Source: The Financial ProphetUtilizing the company's projected 30% growth rate through 2025 and a slight drop-off through 2027 gets us to approximately $7.3 billion in revenues in 2027. The 7-9 times forward sales multiple projections are not high considering Palantir's robust growth and substantial profitability potential. Microsoft (MSFT), a software company with much slower growth, trades at about eight times forward sales. Nvidia (NVDA), a growth company with significantly slower growth, trades at approximately 12 times forward sales projections. Moreover, many other growth companies are trading at substantially higher multiples than ten times sales.Palantir could command a P/S multiple of 7-9 or significantly higher in the coming years, possibly making the stock one of the best buys for the next decade. Therefore, the market will probably start weighing the company's stock instead of voting for it in the coming years, and Palantir's share price will likely advance much higher.Risks To PalantirDespite my bullish outlook for Palantir, market participants should consider several potential risks associated with this investment. While the growth story is strong at Palantir, shares are not cheap by traditional metrics. Furthermore, the company's earnings are still minimal and may not increase as much as I envision. Moreover, if the company's growth picture were to turn less bullish, the stock could head in the wrong direction. For instance, if Palantir lost favor with the government or had a data breach, the stock could experience a notable decline. Please consider these and other risks carefully before investing in Palantir.","news_type":1,"symbols_score_info":{"PLTR":0.9}},"isVote":1,"tweetType":1,"viewCount":1151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9075321734,"gmtCreate":1658151670428,"gmtModify":1676536112825,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4094293265127660","idStr":"4094293265127660"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9075321734","repostId":"2252476857","repostType":4,"isVote":1,"tweetType":1,"viewCount":1486,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9013590831,"gmtCreate":1648741436948,"gmtModify":1676534389795,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4094293265127660","idStr":"4094293265127660"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/A7RU.SI\">$KEPPEL INFRA TRUST WEF 2015(A7RU.SI)$</a>Good","listText":"<a href=\"https://ttm.financial/S/A7RU.SI\">$KEPPEL INFRA TRUST WEF 2015(A7RU.SI)$</a>Good","text":"$KEPPEL INFRA TRUST WEF 2015(A7RU.SI)$Good","images":[{"img":"https://community-static.tradeup.com/news/8d5f245476e2e9d553dac452c511b16d","width":"1170","height":"2292"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013590831","isVote":1,"tweetType":1,"viewCount":1067,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9074312794,"gmtCreate":1658295073218,"gmtModify":1676536136903,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4094293265127660","idStr":"4094293265127660"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9074312794","repostId":"1151508320","repostType":4,"repost":{"id":"1151508320","kind":"news","pubTimestamp":1658289497,"share":"https://ttm.financial/m/news/1151508320?lang=en_US&edition=fundamental","pubTime":"2022-07-20 11:58","market":"us","language":"en","title":"Palantir: Possibly The Buy Of The Decade Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1151508320","media":"Seeking Alpha","summary":"SummaryPalantir has been one of the worst-hit stocks since the growth meltdown began last year.While","content":"<html><head></head><body><p><b>Summary</b></p><ul><li>Palantir has been one of the worst-hit stocks since the growth meltdown began last year.</li><li>While dilution, SBC, lack of profitability, and a high valuation are valid concerns, they are probably transitory factors.</li><li>The market has been a voting machine for Palantir's stock recently, but it should price the company's shares much higher long term.</li></ul><p>Palantir Technologies Inc. (NYSE:PLTR) is one of the most controversial companies. The company's market cap is floating at around $18 billion, more than ten times TTM sales. Moreover, the company is infamous for its dilution and has never shown a net profit in a single quarter. Therefore, it is no surprise that since the growth meltdown began last year, Palantir has been one of the worst-hit stocks. The company experienced an epic drop of 80% from peak to trough, but the share price has begun to recover.</p><p><b>PLTR 1-Year</b></p><p><img src=\"https://static.tigerbbs.com/9de65d4b86e4ec1d262d3162399e05b7\" tg-width=\"640\" tg-height=\"676\" referrerpolicy=\"no-referrer\"/></p><p>PLTR (StockCharts.com)</p><p>Benjamin Graham may have said it best - "In the short term, the market is a voting machine, but in the long run, it is a weighing machine." Mr. Graham was a brilliant investor, and the saying applies exceptionally well to Palantir, in my view. The market seemed crazy about Palantir when the stock was at $20 or $30, but is not fond of Palantir these days. The stock was severely diluted after its IPO, and the criticisms of stock-based compensation ("SBC") continue today. Moreover, growth and high multiple stocks are not as popular as they were throughout most of 2021, and with a possible recession approaching, the market is voting "No" on Palantir.</p><p>However, let's weigh Palantir's stock instead of voting for it. Dilution and SBC compensation are common phenomena with IPOs, and Palantir is not an exception. Let's not look at past sales, but let us focus on the company's revenue growth and earning potential. Additionally, let's consider Palantir's unique, leading, and dominant market position and how it could impact future growth prospects and profitability potential. Moreover, Palantir's growth runway is massive, and its profitability potential is vast, making the stock possibly one of the best buys for the next decade.</p><p><b>Palantir - The Government's Favorite Contractor</b></p><p>One of Palantir's most unique facets is its dominant position as a government contractor. The company provides software solutions through its Gotham program to numerous government agencies. Some of Palantir's government clients include the U.S. military, intelligence, and police. More specifically, the FBI, DOD, CIA, NSA, and many other agencies use Palantir's linked databases,data mining solutions, analysis software, and much more. Furthermore, Palantir services the NHS, FDA, and other agencies. While Palantir is growing its corporate business aggressively, it still derived most of its revenues (54%) from government contracts last quarter. Advantageously, Palantir gets a substantial portion of its revenues from the government as the government is famous for its loose spending policies. Moreover, the company should continue growing government revenues, and even when a recession comes, the government will continue its spending.</p><p><b>It's All About Growth - For Now</b></p><p>I hear a lot of complaints that Palantir is not profitable, but Palantir does not need to be profitable. The company is growing at more than 30%.</p><p><img src=\"https://static.tigerbbs.com/86703bab0eb031120a21a04070660751\" tg-width=\"640\" tg-height=\"318\" referrerpolicy=\"no-referrer\"/></p><p>Q1 Highlights (investors.palantir.com)</p><p>Palantir's growth metrics are tremendous. 31% YoY revenue growth, 54% YoY commercial revenue growth, 136% YoY U.S. commercial revenue growth, and 86% YoY customer count growth. While the company's government business remains its anchor, we see Palantir growing its commercial business aggressively now. Moreover, we should continue seeing robust growth from the government and corporate clients as the company moves on. For full-year 2022, the company expects to show an adjusted operating margin of approximately 27% and anticipates providing30% annual growthor greater through 2025.</p><p><b>Be Patient - Profitability Will Come</b></p><p>Palantir is a high-growth company. Therefore, there is no need for it to be profitable right now. The company needs to focus on growing operations, increasing market share, and setting up future profitability potential. However, when it's time, Palantir should be exceptionally profitable.</p><p><b>Statement of Operations</b></p><p><img src=\"https://static.tigerbbs.com/c68e8a7494948e5f170dc64534d1921a\" tg-width=\"640\" tg-height=\"663\" referrerpolicy=\"no-referrer\"/></p><p>Statement of Operations (investors.palantir.com)</p><p>Last quarter, the company's gross profit increased by32% YoY. At the same time, Palantir's operating expenses increased by only 2.6% YoY. Therefore, the operating loss last quarter was much narrower than last year's, just $39.4 million vs. $114 million one year ago. Moreover, Palantir's gross margin came in at a whopping 78.6% the previous quarter, even higher than the 78.3% from one year ago. Thus, we see Palantir is growing increasingly profitable. As the company's gross profit continues to increase, it will start outweighing the company's operating expenses significantly, leading to substantial increases in operating income, net profit, and EPS.</p><p><b>Dilution - Not a Problem Anymore</b></p><p>We see that Palantir's share count rose by about 11% YoY. Therefore, Palantir is still diluting, but not nearly as much as it did when the company initially went public. Palantir went public with only about476 million shares. However, the company has more than 2 billion shares outstanding now. Yet, much of the dilation occurred early, essentially right after the company went public. Roughly six months after going public, the company already had nearly1.8 billion shares. Since then, SBC expenses have been declining significantly and are likely to continue falling as the company advances. Additionally, increased SBC is a common phenomenon with IPOs and is not a Palantir-isolated phenomenon.</p><p><b>SBS Expenses</b></p><p><img src=\"https://static.tigerbbs.com/5f9e8cbaa81a63e7986e0b033c550680\" tg-width=\"640\" tg-height=\"185\" referrerpolicy=\"no-referrer\"/></p><p>SBS Expenses (investors.palantir.com)</p><p>We see that, despite significantly higher revenues and income, SBC is down by about 23% YoY. This dynamic implies that the trend of lower SBC expenses should continue. Also, if we factor out the SBC expenses, we see that Palantir should become remarkably profitable. Minus SBC, the company's cost of revenue was only about<i>$82.8 million</i>, implying a gross margin of nearly 82% for Palantir. Minus SBC, Palantir's operating income would have been around<i>$110 million</i> last quarter, illustrating an operating margin of approximately 25%.</p><p>The company would have even recorded a small net income of about<i>$10 million</i> once SBC expenses are removed from the equation. The company reported an adjusted EPS of $0.02, illustrating that the company can be profitable right now, even while growing YoY revenues at more than 30%. Therefore, we see that Palantir has the potential to become increasingly prosperous. As the company's revenues and gross profit continue to rise, its operating expenses should increase modestly, and the SBC should continue declining significantly in proportion to the company's revenues. Thus, Palantir's profitability metrics should improve dramatically in the coming years.</p><p><b>Palantir - May Be Recession Proof</b></p><p>There's much concern about the upcoming recession. However, Palantir is in a unique position, as much of the company's revenues come from government contracts. The company's corporate clients are also not likely to reduce their reliance on Palantir's services, as the company provides essential solutions relating to data analytics, cybersecurity, and other critical aspects. Therefore, even in a recession, Palantir's growth should continue increasing, making it one of the best long-term buys in the market right now.</p><p><b>A Closer Look At Palantir's Valuation</b></p><p>Palantir should deliver roughly $2.6 billion in revenues next year, placing its forward P/S multiple at approximately 7. However, Palantir is a dominant market-leading high-growth company with remarkable profitability potential. Recently, the stock got voted down to a 5x forward sales multiple, when the stock fell down to $6. Now at $9 Palantir is trading at about 7 times forward sales, but it may trade at a significantly higher sales multiple down the line. Many companies with far less growth potential sell at significantly higher sales multiples.</p><p><b>Therefore, here's how Palantir's financials could look like as the company advances:</b></p><table><tbody><tr><td><b>Year</b></td><td><b>2022</b></td><td><b>2023</b></td><td><b>2024</b></td><td><b>2025</b></td><td><b>2026</b></td><td><b>2027</b></td></tr><tr><td>Revenue $</td><td>2b</td><td>2.6b</td><td>3.4b</td><td>4.4b</td><td>5.7b</td><td>7.3b</td></tr><tr><td>Revenue growth</td><td>30%</td><td>30%</td><td>30%</td><td>30%</td><td>28%</td><td>25%</td></tr><tr><td>Forward P/S ratio</td><td>7</td><td>8</td><td>9</td><td>9</td><td>8</td><td>8</td></tr><tr><td>Price</td><td>$9</td><td>$14</td><td>$21</td><td>$27</td><td>$32</td><td>$40</td></tr></tbody></table><p>Source: The Financial Prophet</p><p>Utilizing the company's projected 30% growth rate through 2025 and a slight drop-off through 2027 gets us to approximately <i>$7.3 billion</i> in revenues in 2027. The 7-9 times forward sales multiple projections are not high considering Palantir's robust growth and substantial profitability potential. Microsoft (MSFT), a software company with much slower growth, trades at about eight times forward sales. Nvidia (NVDA), a growth company with significantly slower growth, trades at approximately 12 times forward sales projections. Moreover, many other growth companies are trading at substantially higher multiples than ten times sales.</p><p>Palantir could command a P/S multiple of 7-9 or significantly higher in the coming years, possibly making the stock one of the best buys for the next decade. Therefore, the market will probably start weighing the company's stock instead of voting for it in the coming years, and Palantir's share price will likely advance much higher.</p><p><b>Risks To Palantir</b></p><p>Despite my bullish outlook for Palantir, market participants should consider several potential risks associated with this investment. While the growth story is strong at Palantir, shares are not cheap by traditional metrics. Furthermore, the company's earnings are still minimal and may not increase as much as I envision. Moreover, if the company's growth picture were to turn less bullish, the stock could head in the wrong direction. For instance, if Palantir lost favor with the government or had a data breach, the stock could experience a notable decline. Please consider these and other risks carefully before investing in Palantir.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir: Possibly The Buy Of The Decade Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir: Possibly The Buy Of The Decade Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-07-20 11:58 GMT+8 <a href=https://seekingalpha.com/article/4524288-palantir-possibly-the-buy-of-the-decade-now><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryPalantir has been one of the worst-hit stocks since the growth meltdown began last year.While dilution, SBC, lack of profitability, and a high valuation are valid concerns, they are probably ...</p>\n\n<a href=\"https://seekingalpha.com/article/4524288-palantir-possibly-the-buy-of-the-decade-now\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4524288-palantir-possibly-the-buy-of-the-decade-now","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151508320","content_text":"SummaryPalantir has been one of the worst-hit stocks since the growth meltdown began last year.While dilution, SBC, lack of profitability, and a high valuation are valid concerns, they are probably transitory factors.The market has been a voting machine for Palantir's stock recently, but it should price the company's shares much higher long term.Palantir Technologies Inc. (NYSE:PLTR) is one of the most controversial companies. The company's market cap is floating at around $18 billion, more than ten times TTM sales. Moreover, the company is infamous for its dilution and has never shown a net profit in a single quarter. Therefore, it is no surprise that since the growth meltdown began last year, Palantir has been one of the worst-hit stocks. The company experienced an epic drop of 80% from peak to trough, but the share price has begun to recover.PLTR 1-YearPLTR (StockCharts.com)Benjamin Graham may have said it best - \"In the short term, the market is a voting machine, but in the long run, it is a weighing machine.\" Mr. Graham was a brilliant investor, and the saying applies exceptionally well to Palantir, in my view. The market seemed crazy about Palantir when the stock was at $20 or $30, but is not fond of Palantir these days. The stock was severely diluted after its IPO, and the criticisms of stock-based compensation (\"SBC\") continue today. Moreover, growth and high multiple stocks are not as popular as they were throughout most of 2021, and with a possible recession approaching, the market is voting \"No\" on Palantir.However, let's weigh Palantir's stock instead of voting for it. Dilution and SBC compensation are common phenomena with IPOs, and Palantir is not an exception. Let's not look at past sales, but let us focus on the company's revenue growth and earning potential. Additionally, let's consider Palantir's unique, leading, and dominant market position and how it could impact future growth prospects and profitability potential. Moreover, Palantir's growth runway is massive, and its profitability potential is vast, making the stock possibly one of the best buys for the next decade.Palantir - The Government's Favorite ContractorOne of Palantir's most unique facets is its dominant position as a government contractor. The company provides software solutions through its Gotham program to numerous government agencies. Some of Palantir's government clients include the U.S. military, intelligence, and police. More specifically, the FBI, DOD, CIA, NSA, and many other agencies use Palantir's linked databases,data mining solutions, analysis software, and much more. Furthermore, Palantir services the NHS, FDA, and other agencies. While Palantir is growing its corporate business aggressively, it still derived most of its revenues (54%) from government contracts last quarter. Advantageously, Palantir gets a substantial portion of its revenues from the government as the government is famous for its loose spending policies. Moreover, the company should continue growing government revenues, and even when a recession comes, the government will continue its spending.It's All About Growth - For NowI hear a lot of complaints that Palantir is not profitable, but Palantir does not need to be profitable. The company is growing at more than 30%.Q1 Highlights (investors.palantir.com)Palantir's growth metrics are tremendous. 31% YoY revenue growth, 54% YoY commercial revenue growth, 136% YoY U.S. commercial revenue growth, and 86% YoY customer count growth. While the company's government business remains its anchor, we see Palantir growing its commercial business aggressively now. Moreover, we should continue seeing robust growth from the government and corporate clients as the company moves on. For full-year 2022, the company expects to show an adjusted operating margin of approximately 27% and anticipates providing30% annual growthor greater through 2025.Be Patient - Profitability Will ComePalantir is a high-growth company. Therefore, there is no need for it to be profitable right now. The company needs to focus on growing operations, increasing market share, and setting up future profitability potential. However, when it's time, Palantir should be exceptionally profitable.Statement of OperationsStatement of Operations (investors.palantir.com)Last quarter, the company's gross profit increased by32% YoY. At the same time, Palantir's operating expenses increased by only 2.6% YoY. Therefore, the operating loss last quarter was much narrower than last year's, just $39.4 million vs. $114 million one year ago. Moreover, Palantir's gross margin came in at a whopping 78.6% the previous quarter, even higher than the 78.3% from one year ago. Thus, we see Palantir is growing increasingly profitable. As the company's gross profit continues to increase, it will start outweighing the company's operating expenses significantly, leading to substantial increases in operating income, net profit, and EPS.Dilution - Not a Problem AnymoreWe see that Palantir's share count rose by about 11% YoY. Therefore, Palantir is still diluting, but not nearly as much as it did when the company initially went public. Palantir went public with only about476 million shares. However, the company has more than 2 billion shares outstanding now. Yet, much of the dilation occurred early, essentially right after the company went public. Roughly six months after going public, the company already had nearly1.8 billion shares. Since then, SBC expenses have been declining significantly and are likely to continue falling as the company advances. Additionally, increased SBC is a common phenomenon with IPOs and is not a Palantir-isolated phenomenon.SBS ExpensesSBS Expenses (investors.palantir.com)We see that, despite significantly higher revenues and income, SBC is down by about 23% YoY. This dynamic implies that the trend of lower SBC expenses should continue. Also, if we factor out the SBC expenses, we see that Palantir should become remarkably profitable. Minus SBC, the company's cost of revenue was only about$82.8 million, implying a gross margin of nearly 82% for Palantir. Minus SBC, Palantir's operating income would have been around$110 million last quarter, illustrating an operating margin of approximately 25%.The company would have even recorded a small net income of about$10 million once SBC expenses are removed from the equation. The company reported an adjusted EPS of $0.02, illustrating that the company can be profitable right now, even while growing YoY revenues at more than 30%. Therefore, we see that Palantir has the potential to become increasingly prosperous. As the company's revenues and gross profit continue to rise, its operating expenses should increase modestly, and the SBC should continue declining significantly in proportion to the company's revenues. Thus, Palantir's profitability metrics should improve dramatically in the coming years.Palantir - May Be Recession ProofThere's much concern about the upcoming recession. However, Palantir is in a unique position, as much of the company's revenues come from government contracts. The company's corporate clients are also not likely to reduce their reliance on Palantir's services, as the company provides essential solutions relating to data analytics, cybersecurity, and other critical aspects. Therefore, even in a recession, Palantir's growth should continue increasing, making it one of the best long-term buys in the market right now.A Closer Look At Palantir's ValuationPalantir should deliver roughly $2.6 billion in revenues next year, placing its forward P/S multiple at approximately 7. However, Palantir is a dominant market-leading high-growth company with remarkable profitability potential. Recently, the stock got voted down to a 5x forward sales multiple, when the stock fell down to $6. Now at $9 Palantir is trading at about 7 times forward sales, but it may trade at a significantly higher sales multiple down the line. Many companies with far less growth potential sell at significantly higher sales multiples.Therefore, here's how Palantir's financials could look like as the company advances:Year202220232024202520262027Revenue $2b2.6b3.4b4.4b5.7b7.3bRevenue growth30%30%30%30%28%25%Forward P/S ratio789988Price$9$14$21$27$32$40Source: The Financial ProphetUtilizing the company's projected 30% growth rate through 2025 and a slight drop-off through 2027 gets us to approximately $7.3 billion in revenues in 2027. The 7-9 times forward sales multiple projections are not high considering Palantir's robust growth and substantial profitability potential. Microsoft (MSFT), a software company with much slower growth, trades at about eight times forward sales. Nvidia (NVDA), a growth company with significantly slower growth, trades at approximately 12 times forward sales projections. Moreover, many other growth companies are trading at substantially higher multiples than ten times sales.Palantir could command a P/S multiple of 7-9 or significantly higher in the coming years, possibly making the stock one of the best buys for the next decade. Therefore, the market will probably start weighing the company's stock instead of voting for it in the coming years, and Palantir's share price will likely advance much higher.Risks To PalantirDespite my bullish outlook for Palantir, market participants should consider several potential risks associated with this investment. While the growth story is strong at Palantir, shares are not cheap by traditional metrics. Furthermore, the company's earnings are still minimal and may not increase as much as I envision. Moreover, if the company's growth picture were to turn less bullish, the stock could head in the wrong direction. For instance, if Palantir lost favor with the government or had a data breach, the stock could experience a notable decline. Please consider these and other risks carefully before investing in Palantir.","news_type":1,"symbols_score_info":{"PLTR":0.9}},"isVote":1,"tweetType":1,"viewCount":1151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9017390765,"gmtCreate":1649741798002,"gmtModify":1676534562334,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4094293265127660","idStr":"4094293265127660"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>:)","listText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>:)","text":"$SINGAPORE AIRLINES LTD(C6L.SI)$:)","images":[{"img":"https://community-static.tradeup.com/news/79c455690ee68cfc70802d74bd5b2c47","width":"1170","height":"2292"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9017390765","isVote":1,"tweetType":1,"viewCount":1001,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9009684124,"gmtCreate":1640653480761,"gmtModify":1676533531738,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4094293265127660","idStr":"4094293265127660"},"themes":[],"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009684124","repostId":"1156481741","repostType":4,"repost":{"id":"1156481741","kind":"news","pubTimestamp":1640652473,"share":"https://ttm.financial/m/news/1156481741?lang=en_US&edition=fundamental","pubTime":"2021-12-28 08:47","market":"us","language":"en","title":"Is Merck Stock A Buy Or Sell After FDA Authorizes Its Covid Pill?","url":"https://stock-news.laohu8.com/highlight/detail?id=1156481741","media":"Investors","summary":"The Food and Drug Administration authorized Merck's (MRK) antiviral Covid pill, molnupiravir. But Me","content":"<p>The Food and Drug Administration authorized <b>Merck</b>'s (MRK) antiviral Covid pill, molnupiravir. But Merck stock remains under pressure.</p>\n<p>The FDA authorized the Ridgeback Biotherapeutics-partnered pill for emergency use when other options aren't available or appropriate.<b>Pfizer</b>(PFE) also gained authorization for its two-pill regimen, Paxlovid. Paxlovid proved more effective in clinical testing. Further, molnupiravir carries a cancer risk and could lead to birth defects in unborn children.</p>\n<p>Merck's molnupiravir cut the risk of Covid-related hospitalizations or death by 30% when patients began treatment within five days of symptoms appearing. Paxlovid reduced the same risk by 89% for patients who began treatment within three days of symptom onset.</p>\n<p>Merck stock is well off highs it achieved in November. Bullishly, the company beat third-quarter expectations and offered an upbeat 2021 outlook that didn't include the potential impact of the antiviral pill. Molnupiravir is also allowed in the U.K. and Japan.</p>\n<p>Merck expects to produce 10 million courses of molnupiravir this year and at least 20 million in 2022. It has supply agreements in place with more than 30 countries worldwide, including the U.S.</p>\n<p>So, all in all, is Merck stock a buy or a sell right now?</p>\n<p><b>Merck Stock Fundamentals: Sales Top</b></p>\n<p>During the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.</p>\n<p>Merck also provided guidance following its <b>Organon</b>(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.</p>\n<p>The company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.</p>\n<p>But revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.</p>\n<p>Overall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.</p>\n<p>In the current quarter, analysts polled by FactSet expect Merck to earn $1.52 per share on $13.16 billion in sales. On a year-over-year basis, earnings would surge about 21% and sales would rise north of 5%.</p>\n<p><b>What Do Annual Metrics Say About Merck?</b></p>\n<p>As Dec. 27, Merck stock was down slightly for the year. Shares recently hit at least a three-decade high, but have since tumbled.</p>\n<p>Last year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.</p>\n<p>For 2021, analysts expect sales to rise a fraction to $48.44 billion. Income is projected to inch 2.8% higher to $5.82 a share. That follows 14% growth in 2020.</p>\n<p>The stock ranks 6th by Composite Rating in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks No. 51 out of 197 groups tracked by Investor's Business Daily.</p>\n<p><b>Technical Analysis Of The Pharmaceutical Company</b></p>\n<p>Merck stock has a Composite Rating of 81 out of a best-possible 99. The CR is a measure of a stock's key growth metrics over the past 12 months. This puts Merck stock within the top 19% of all stocks, regardless of industry group.</p>\n<p>Shares also have a Relative Strength Rating of 57, reflecting the 12-month performance of Merck stock. This means the pharmaceutical stock ranks beneath the top one-third all stocks in terms of performance.</p>\n<p>It's also key to watch chart patterns. Merck stock broke out of a flat base with abuy point at 79.33 on Oct. 1, according to MarketSmith.com. But shares fell as much as 7% below their entry on Nov. 30. That triggered a sell signal. Investors are encouraged to sell when a stock is 7%-8% below its entry.</p>\n<p>Merck stock also recently undercut its 50-day and 200-day moving averages. Both are sell signals.</p>\n<p><b>Merck Stock News: Merck Grabs Covid Deal</b></p>\n<p>Merck's molnupiravir is now authorized in the U.S., U.K. and Japan.</p>\n<p>In addition to Merck and Pfizer,<b>Atea Pharmaceuticals</b>(AVIR) and <b>Enanta Pharmaceuticals</b>(ENTA) working on oral Covid drugs.<b>Roche</b>(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.</p>\n<p>Analysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from <b>Regeneron Pharmaceuticals</b>(REGN),<b>Eli Lilly</b>(LLY) and <b>Vir Biotechnology</b>(VIR). Antibody drugs must be given by health care professionals.</p>\n<p>But there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.</p>\n<p>Bearishly, the FDA placed a study testing an HIV prevention drug, islatravir, on clinical hold. Several patients showed decreased in key immune cells. Merck and <b>Gilead Sciences</b>(GILD) also decided to stop testing a regimen of islatravir and Gilead's lenacapavir in HIV patients.</p>\n<p>Merck also recently finished acquiring Acceleron.</p>\n<p>In early March, President Joe Biden announced Merck would help<b>Johnson & Johnson</b>(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.</p>\n<p><b>Is Merck Stock A Buy Now?</b></p>\n<p>Based on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.</p>\n<p>There are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.</p>\n<p>Still, big stocks like Merck can add gains without hitting massive growth streaks.</p>","source":"lsy1610449120050","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Merck Stock A Buy Or Sell After FDA Authorizes Its Covid Pill?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Merck Stock A Buy Or Sell After FDA Authorizes Its Covid Pill?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 08:47 GMT+8 <a href=https://www.investors.com/news/technology/merck-stock-buy-now/?src=A00220><strong>Investors</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Food and Drug Administration authorized Merck's (MRK) antiviral Covid pill, molnupiravir. But Merck stock remains under pressure.\nThe FDA authorized the Ridgeback Biotherapeutics-partnered pill ...</p>\n\n<a href=\"https://www.investors.com/news/technology/merck-stock-buy-now/?src=A00220\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.investors.com/news/technology/merck-stock-buy-now/?src=A00220","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156481741","content_text":"The Food and Drug Administration authorized Merck's (MRK) antiviral Covid pill, molnupiravir. But Merck stock remains under pressure.\nThe FDA authorized the Ridgeback Biotherapeutics-partnered pill for emergency use when other options aren't available or appropriate.Pfizer(PFE) also gained authorization for its two-pill regimen, Paxlovid. Paxlovid proved more effective in clinical testing. Further, molnupiravir carries a cancer risk and could lead to birth defects in unborn children.\nMerck's molnupiravir cut the risk of Covid-related hospitalizations or death by 30% when patients began treatment within five days of symptoms appearing. Paxlovid reduced the same risk by 89% for patients who began treatment within three days of symptom onset.\nMerck stock is well off highs it achieved in November. Bullishly, the company beat third-quarter expectations and offered an upbeat 2021 outlook that didn't include the potential impact of the antiviral pill. Molnupiravir is also allowed in the U.K. and Japan.\nMerck expects to produce 10 million courses of molnupiravir this year and at least 20 million in 2022. It has supply agreements in place with more than 30 countries worldwide, including the U.S.\nSo, all in all, is Merck stock a buy or a sell right now?\nMerck Stock Fundamentals: Sales Top\nDuring the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.\nMerck also provided guidance following its Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.\nThe company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.\nBut revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.\nOverall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.\nIn the current quarter, analysts polled by FactSet expect Merck to earn $1.52 per share on $13.16 billion in sales. On a year-over-year basis, earnings would surge about 21% and sales would rise north of 5%.\nWhat Do Annual Metrics Say About Merck?\nAs Dec. 27, Merck stock was down slightly for the year. Shares recently hit at least a three-decade high, but have since tumbled.\nLast year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.\nFor 2021, analysts expect sales to rise a fraction to $48.44 billion. Income is projected to inch 2.8% higher to $5.82 a share. That follows 14% growth in 2020.\nThe stock ranks 6th by Composite Rating in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks No. 51 out of 197 groups tracked by Investor's Business Daily.\nTechnical Analysis Of The Pharmaceutical Company\nMerck stock has a Composite Rating of 81 out of a best-possible 99. The CR is a measure of a stock's key growth metrics over the past 12 months. This puts Merck stock within the top 19% of all stocks, regardless of industry group.\nShares also have a Relative Strength Rating of 57, reflecting the 12-month performance of Merck stock. This means the pharmaceutical stock ranks beneath the top one-third all stocks in terms of performance.\nIt's also key to watch chart patterns. Merck stock broke out of a flat base with abuy point at 79.33 on Oct. 1, according to MarketSmith.com. But shares fell as much as 7% below their entry on Nov. 30. That triggered a sell signal. Investors are encouraged to sell when a stock is 7%-8% below its entry.\nMerck stock also recently undercut its 50-day and 200-day moving averages. Both are sell signals.\nMerck Stock News: Merck Grabs Covid Deal\nMerck's molnupiravir is now authorized in the U.S., U.K. and Japan.\nIn addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.\nAnalysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.\nBut there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.\nBearishly, the FDA placed a study testing an HIV prevention drug, islatravir, on clinical hold. Several patients showed decreased in key immune cells. Merck and Gilead Sciences(GILD) also decided to stop testing a regimen of islatravir and Gilead's lenacapavir in HIV patients.\nMerck also recently finished acquiring Acceleron.\nIn early March, President Joe Biden announced Merck would helpJohnson & Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.\nIs Merck Stock A Buy Now?\nBased on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.\nThere are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.\nStill, big stocks like Merck can add gains without hitting massive growth streaks.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":844,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9059217846,"gmtCreate":1654387326486,"gmtModify":1676535438264,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4094293265127660","idStr":"4094293265127660"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9059217846","repostId":"2240127730","repostType":4,"repost":{"id":"2240127730","kind":"highlight","pubTimestamp":1654320478,"share":"https://ttm.financial/m/news/2240127730?lang=en_US&edition=fundamental","pubTime":"2022-06-04 13:27","market":"us","language":"en","title":"Microsoft’s Dollar Alarm Raises New Worry for Software Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2240127730","media":"Bloomberg","summary":"(Bloomberg) -- Software makers that have been battered amid this year’s stock slump were dealt anoth","content":"<div>\n<p>(Bloomberg) -- Software makers that have been battered amid this year’s stock slump were dealt another blow this week when Microsoft Corp. warned of even more headwinds coming down the pike.The world’...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-06-03/microsoft-s-dollar-alarm-raises-new-worry-for-software-stocks?srnd=premium-asia\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft’s Dollar Alarm Raises New Worry for Software Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft’s Dollar Alarm Raises New Worry for Software Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-04 13:27 GMT+8 <a href=https://www.bloomberg.com/news/articles/2022-06-03/microsoft-s-dollar-alarm-raises-new-worry-for-software-stocks?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Software makers that have been battered amid this year’s stock slump were dealt another blow this week when Microsoft Corp. warned of even more headwinds coming down the pike.The world’...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-06-03/microsoft-s-dollar-alarm-raises-new-worry-for-software-stocks?srnd=premium-asia\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADBE":"Adobe","CRM":"赛富时","MSFT":"微软","ORCL":"甲骨文"},"source_url":"https://www.bloomberg.com/news/articles/2022-06-03/microsoft-s-dollar-alarm-raises-new-worry-for-software-stocks?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2240127730","content_text":"(Bloomberg) -- Software makers that have been battered amid this year’s stock slump were dealt another blow this week when Microsoft Corp. warned of even more headwinds coming down the pike.The world’s largest software maker cut its profit forecast for the current quarter on Thursday and blamed the surging US dollar for an upcoming drag on its earnings to the tune of $460 million. The company’s rare mid-season revision took markets by surprise and briefly sent futures on the S&P 500 Index tumbling.Microsoft and other large US software makers such as Oracle Corp. and Adobe Inc. , have complex global operations and higher exposure to foreign currencies. The US Dollar Index has risen more than 7% off a January low, and last month hit its highest in two decades. The more expensive dollar is bound to add to pressures already threatening the companies’ margins such as higher costs.“A strong dollar will be a recurring theme across many large software companies, as most generate over one-third of their sales outside the US,” said Anurag Rana, senior analyst with Bloomberg Intelligence.Soaring U.S. Treasury yields and expectations of tighter monetary policy from the Federal Reserve have caused investors to flee software stocks with pricey valuations and whose profits are expected to be delivered far in the future.The iShares Expanded Tech-Software Sector ETF is down 24% in 2022, including a drop of 1.6% in Friday’s session. A Goldman Sachs basket of the priciest software names is down more than 45%, while the broad S&P 500 Index is down 14%. Microsoft is on track to end the week 1.2% lower.Dollar HedgeWall Street has been encouraged by strong financial results from software makers this earnings season. Salesforce Inc. this week gave a bullish full-year forecast but said results were hurt by the dollar’s strength, and warned that it expects the issue to extend into the second quarter.Companies with larger exposure to currencies like Salesforce will have to look into hedging strategies to protect against the dollar strength, said Brendan McKenna, a strategist at Wells Fargo. He sees the dollar bulking up against most developed countries’ currencies, as well as those from emerging markets, with few exceptions.For now, analysts have remained sanguine about profits lost to foreign-exchange rates, focusing instead on strong fundamentals that point to the group’s resilience in the face of slowing economic growth.But for some investors, there are still too many risks to justify piling back into software stocks despite more attractive prices.“They’re more attractive than they were, but we won’t chase the quality names lower thinking they’re bargains yet,” Stephen Hoedt, managing director of equity research at Key Private Bank. “Cheap can quickly become cheaper in a rising-rate environment.”","news_type":1,"symbols_score_info":{"CRM":0.9,"ORCL":0.9,"ADBE":0.9,"MSFT":1}},"isVote":1,"tweetType":1,"viewCount":1022,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9019306648,"gmtCreate":1648521818415,"gmtModify":1676534349759,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4094293265127660","idStr":"4094293265127660"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>gogo","listText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>gogo","text":"$SINGAPORE AIRLINES LTD(C6L.SI)$gogo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9019306648","isVote":1,"tweetType":1,"viewCount":741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":525220862689528,"gmtCreate":1769253667813,"gmtModify":1769253670900,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4094293265127660","idStr":"4094293265127660"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&P 500 ETF(VOO)$ </a> oh yey ","listText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&P 500 ETF(VOO)$ </a> oh yey ","text":"$Vanguard S&P 500 ETF(VOO)$ oh yey","images":[{"img":"https://community-static.tradeup.com/news/c28aa3ccc44c53bd36c01c5ff7f7d5b8","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/525220862689528","isVote":1,"tweetType":1,"viewCount":78,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":496282594333192,"gmtCreate":1762185165675,"gmtModify":1762185168985,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4094293265127660","idStr":"4094293265127660"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/M44U.SI\">$Mapletree Log Tr(M44U.SI)$ </a> ","listText":"<a href=\"https://ttm.financial/S/M44U.SI\">$Mapletree Log Tr(M44U.SI)$ </a> ","text":"$Mapletree Log Tr(M44U.SI)$","images":[{"img":"https://community-static.tradeup.com/news/7414e839f24d8ffbecf94de3421f1873","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/496282594333192","isVote":1,"tweetType":1,"viewCount":925,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9918420655,"gmtCreate":1664435205377,"gmtModify":1676537454866,"author":{"id":"4094293265127660","authorId":"4094293265127660","name":"Sherry0000","avatar":"https://static.tigerbbs.com/5976eb8b8d34e9053356f5790ff80cbf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4094293265127660","idStr":"4094293265127660"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9918420655","repostId":"2271737074","repostType":4,"repost":{"id":"2271737074","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1664406595,"share":"https://ttm.financial/m/news/2271737074?lang=en_US&edition=fundamental","pubTime":"2022-09-29 07:09","market":"us","language":"en","title":"US STOCKS-Wall Street Ends Sharply Higher as Treasury Yields Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2271737074","media":"Reuters","summary":"Apple drops on concerns about iPhone demandTreasury prices rebound after BoE decisionS&P 500 records largest one-day gain since Aug. 10Indexes: Dow +1.88%, S&P 500 +1.97%, Nasdaq +2.05%Sept 28 (Reuter","content":"<html><head></head><body><ul><li>Apple drops on concerns about iPhone demand</li><li>Treasury prices rebound after BoE decision</li><li>S&P 500 records largest one-day gain since Aug. 10</li><li>Indexes: Dow +1.88%, S&P 500 +1.97%, Nasdaq +2.05%</li></ul><p>Sept 28 (Reuters) - Wall Street ended sharply higher on Wednesday following its recent sell-off, helped by falling Treasury yields, while Apple dropped on concerns about demand for iPhones.</p><p>The S&P 500 recorded its first gain in seven sessions after closing on Tuesday at its lowest since late 2020.</p><p>Interest rate-sensitive megacaps Microsoft, Amazon and <a href=\"https://laohu8.com/S/META\">Meta Platforms</a> rallied as the yield on 10-year Treasury notes fell over 0.26 percentage point in its biggest one-day drop since 2009.</p><p>Pushing yields lower on Treasuries with maturities six months and longer, the Bank of England said it would buy long-dated British bonds in a move aimed at restoring financial stability in markets rocked globally by the fiscal policy of the new government in London.</p><p>"The yield on the two-year Treasury has gone up persistently over the course of the last several weeks, and for the first time we've seen it go down for two days in a row, and that has given equities a breather," said Art Hogan, chief market strategist at B. Riley Wealth.</p><p>Investors have been keenly listening to comments from Federal Reserve officials about the path of monetary policy, with Atlanta Fed President Raphael Bostic on Wednesday backing another 75-basis-point interest rate hike in November. The Fed will likely get borrowing costs to where they need to be by early next year, Federal Reserve Bank of Chicago President Charles Evans said.</p><p>U.S. stocks have been battered in 2022 by worries that an aggressive push by the Fed to raise borrowing costs could throw the economy into a downturn.</p><p>Apple Inc dropped 1.3% after Bloomberg reported the company is dropping plans to increase production of its new iPhones this year after an anticipated surge in demand failed to materialize.</p><p>Apple has been a relative outperformer in 2022's stock market sell-off, down about 15% in the year to date, versus the S&P 500's 22% loss.</p><p>All of the 11 S&P 500 sector indexes rose, led by a 4.4% jump in energy and a 3.2% leap in communication services .</p><p>The Dow Jones Industrial Average rose 1.88% to end at 29,683.74 points, while the S&P 500 gained 1.97% to 3,719.04. It was the S&P 500's largest one-day gain since Aug. 10.</p><p>The Nasdaq Composite jumped 2.05% to 11,051.64.</p><p>Biogen Inc surged 40% after saying its experimental Alzheimer's drug, developed with Japanese partner Eisai Co Ltd , succeeded in slowing cognitive decline.</p><p>Eli Lilly & Co, which is also developing an Alzheimer's drug, jumped 7.5%, and it was among the biggest boosts to the S&P 500 index.</p><p>Advancing issues outnumbered declining ones on the NYSE by a 5.82-to-1 ratio; on Nasdaq, a 3.66-to-1 ratio favored advancers.</p><p>The S&P 500 posted one new 52-week high and 30 new lows; the Nasdaq Composite recorded 26 new highs and 224 new lows.</p><p>Volume on U.S. exchanges was 11.7 billion shares, compared with an 11.4 billion average for the full session over the last 20 trading days.</p><p><img src=\"https://static.tigerbbs.com/da8e9a6ce881361e45c74a1b02609eaf\" tg-width=\"1080\" tg-height=\"1920\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US STOCKS-Wall Street Ends Sharply Higher as Treasury Yields Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS STOCKS-Wall Street Ends Sharply Higher as Treasury Yields Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-09-29 07:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><ul><li>Apple drops on concerns about iPhone demand</li><li>Treasury prices rebound after BoE decision</li><li>S&P 500 records largest one-day gain since Aug. 10</li><li>Indexes: Dow +1.88%, S&P 500 +1.97%, Nasdaq +2.05%</li></ul><p>Sept 28 (Reuters) - Wall Street ended sharply higher on Wednesday following its recent sell-off, helped by falling Treasury yields, while Apple dropped on concerns about demand for iPhones.</p><p>The S&P 500 recorded its first gain in seven sessions after closing on Tuesday at its lowest since late 2020.</p><p>Interest rate-sensitive megacaps Microsoft, Amazon and <a href=\"https://laohu8.com/S/META\">Meta Platforms</a> rallied as the yield on 10-year Treasury notes fell over 0.26 percentage point in its biggest one-day drop since 2009.</p><p>Pushing yields lower on Treasuries with maturities six months and longer, the Bank of England said it would buy long-dated British bonds in a move aimed at restoring financial stability in markets rocked globally by the fiscal policy of the new government in London.</p><p>"The yield on the two-year Treasury has gone up persistently over the course of the last several weeks, and for the first time we've seen it go down for two days in a row, and that has given equities a breather," said Art Hogan, chief market strategist at B. Riley Wealth.</p><p>Investors have been keenly listening to comments from Federal Reserve officials about the path of monetary policy, with Atlanta Fed President Raphael Bostic on Wednesday backing another 75-basis-point interest rate hike in November. The Fed will likely get borrowing costs to where they need to be by early next year, Federal Reserve Bank of Chicago President Charles Evans said.</p><p>U.S. stocks have been battered in 2022 by worries that an aggressive push by the Fed to raise borrowing costs could throw the economy into a downturn.</p><p>Apple Inc dropped 1.3% after Bloomberg reported the company is dropping plans to increase production of its new iPhones this year after an anticipated surge in demand failed to materialize.</p><p>Apple has been a relative outperformer in 2022's stock market sell-off, down about 15% in the year to date, versus the S&P 500's 22% loss.</p><p>All of the 11 S&P 500 sector indexes rose, led by a 4.4% jump in energy and a 3.2% leap in communication services .</p><p>The Dow Jones Industrial Average rose 1.88% to end at 29,683.74 points, while the S&P 500 gained 1.97% to 3,719.04. It was the S&P 500's largest one-day gain since Aug. 10.</p><p>The Nasdaq Composite jumped 2.05% to 11,051.64.</p><p>Biogen Inc surged 40% after saying its experimental Alzheimer's drug, developed with Japanese partner Eisai Co Ltd , succeeded in slowing cognitive decline.</p><p>Eli Lilly & Co, which is also developing an Alzheimer's drug, jumped 7.5%, and it was among the biggest boosts to the S&P 500 index.</p><p>Advancing issues outnumbered declining ones on the NYSE by a 5.82-to-1 ratio; on Nasdaq, a 3.66-to-1 ratio favored advancers.</p><p>The S&P 500 posted one new 52-week high and 30 new lows; the Nasdaq Composite recorded 26 new highs and 224 new lows.</p><p>Volume on U.S. exchanges was 11.7 billion shares, compared with an 11.4 billion average for the full session over the last 20 trading days.</p><p><img src=\"https://static.tigerbbs.com/da8e9a6ce881361e45c74a1b02609eaf\" tg-width=\"1080\" tg-height=\"1920\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2271737074","content_text":"Apple drops on concerns about iPhone demandTreasury prices rebound after BoE decisionS&P 500 records largest one-day gain since Aug. 10Indexes: Dow +1.88%, S&P 500 +1.97%, Nasdaq +2.05%Sept 28 (Reuters) - Wall Street ended sharply higher on Wednesday following its recent sell-off, helped by falling Treasury yields, while Apple dropped on concerns about demand for iPhones.The S&P 500 recorded its first gain in seven sessions after closing on Tuesday at its lowest since late 2020.Interest rate-sensitive megacaps Microsoft, Amazon and Meta Platforms rallied as the yield on 10-year Treasury notes fell over 0.26 percentage point in its biggest one-day drop since 2009.Pushing yields lower on Treasuries with maturities six months and longer, the Bank of England said it would buy long-dated British bonds in a move aimed at restoring financial stability in markets rocked globally by the fiscal policy of the new government in London.\"The yield on the two-year Treasury has gone up persistently over the course of the last several weeks, and for the first time we've seen it go down for two days in a row, and that has given equities a breather,\" said Art Hogan, chief market strategist at B. Riley Wealth.Investors have been keenly listening to comments from Federal Reserve officials about the path of monetary policy, with Atlanta Fed President Raphael Bostic on Wednesday backing another 75-basis-point interest rate hike in November. The Fed will likely get borrowing costs to where they need to be by early next year, Federal Reserve Bank of Chicago President Charles Evans said.U.S. stocks have been battered in 2022 by worries that an aggressive push by the Fed to raise borrowing costs could throw the economy into a downturn.Apple Inc dropped 1.3% after Bloomberg reported the company is dropping plans to increase production of its new iPhones this year after an anticipated surge in demand failed to materialize.Apple has been a relative outperformer in 2022's stock market sell-off, down about 15% in the year to date, versus the S&P 500's 22% loss.All of the 11 S&P 500 sector indexes rose, led by a 4.4% jump in energy and a 3.2% leap in communication services .The Dow Jones Industrial Average rose 1.88% to end at 29,683.74 points, while the S&P 500 gained 1.97% to 3,719.04. It was the S&P 500's largest one-day gain since Aug. 10.The Nasdaq Composite jumped 2.05% to 11,051.64.Biogen Inc surged 40% after saying its experimental Alzheimer's drug, developed with Japanese partner Eisai Co Ltd , succeeded in slowing cognitive decline.Eli Lilly & Co, which is also developing an Alzheimer's drug, jumped 7.5%, and it was among the biggest boosts to the S&P 500 index.Advancing issues outnumbered declining ones on the NYSE by a 5.82-to-1 ratio; on Nasdaq, a 3.66-to-1 ratio favored advancers.The S&P 500 posted one new 52-week high and 30 new lows; the Nasdaq Composite recorded 26 new highs and 224 new lows.Volume on U.S. exchanges was 11.7 billion shares, compared with an 11.4 billion average for the full session over the last 20 trading days.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":3178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}